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Post-mortem histopathology underlying β-
amyloid PET imaging following
flutemetamol F 18 injection
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Chester A. Mathis6, William E. Klunk7, Aruna Chakrabarty8, James Ironside9, Azzam Ismail8, Colin Smith10,
Dietmar R. Thal11,14, Thomas G. Beach12, Gill Farrar2 and Adrian P. L. Smith2*
Abstract
In vivo imaging of fibrillar β-amyloid deposits may assist clinical diagnosis of Alzheimer’s disease (AD), aid treatment
selection for patients, assist clinical trials of therapeutic drugs through subject selection, and be used as an
outcome measure. A recent phase III trial of [18F]flutemetamol positron emission tomography (PET) imaging in 106
end-of-life subjects demonstrated the ability to identify fibrillar β-amyloid by comparing in vivo PET to post-mortem
histopathology. Post-mortem analyses demonstrated a broad and continuous spectrum of β-amyloid pathology in
AD and other dementing and non-dementing disease groups. The GE067-026 trial demonstrated 91% sensitivity
and 90% specificity of [18F]flutemetamol PET by majority read for the presence of moderate or frequent plaques.
The probability of an abnormal [18F]flutemetamol scan increased with neocortical plaque density and AD diagnosis.
All dementia cases with non-AD neurodegenerative diseases and those without histopathological features of β-
amyloid deposits were [18F]flutemetamol negative. Majority PET assessments accurately reflected the amyloid
plaque burden in 90% of cases. However, ten cases demonstrated a mismatch between PET image interpretations
and post-mortem findings. Although tracer retention was best associated with amyloid in neuritic plaques, amyloid
in diffuse plaques and cerebral amyloid angiopathy best explain three [18F]flutemetamol positive cases with
mismatched (sparse) neuritic plaque burden. Advanced cortical atrophy was associated with the seven false
negative [18F]flutemetamol images. The interpretation of images from pathologically equivocal cases was associated
with low reader confidence and inter-reader agreement. Our results support that amyloid in neuritic plaque burden
is the primary form of β-amyloid pathology detectable with [18F]flutemetamol PET imaging. ClinicalTrials.gov
NCT01165554. Registered June 21, 2010; NCT02090855. Registered March 11, 2014.
Keywords: Flutemetamol, PET, Amyloid, Alzheimer’s disease, Neuropathology (4-6 allowed)
Introduction
The relatively modest accuracy of a clinical diagnosis of
Alzheimer’s disease (AD) when compared to the definitive
neuropathological findings at autopsy [4] demonstrates a
current unmet need to detect the neuropathological hall-
marks of AD (β-amyloid plaques and neurofibrillary
tangles) in life. Plaques containing fibrillar β-amyloid are
readily detectable in histological tissue specimens using
dyes with high affinity for amyloid β-sheet structure
(Thioflavin-S and Congo red). Analogues of these dyes
have been radiolabelled to create positron emission
tomography (PET) imaging tracers for detecting β-
amyloid plaques in vivo. PET amyloid tracers such as
Pittsburgh compound B ([11C]PiB) and its derivative
[18F]flutemetamol (VizamylTM) generally can distinguish
between the presence of moderate or frequent amyloid
plaques, required for the diagnosis of AD, or lesser dens-
ities that would rule out AD [24, 61].
Results of recent studies using PET β-amyloid tracers
have shown a good association between tracer retention
and underlying β-amyloid plaques in brain autopsy and bi-
opsy samples [11, 12, 28, 31, 35–38, 47, 50–52, 65–67].
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However, many of these studies have drawn on a pool of
end-of-life subjects with advanced disease, in which aut-
opsy is anticipated shortly after PET imaging and with the
specific goal to demonstrate efficacy. Furthermore these
studies have been required to be measured against semi-
quantitative neuritic plaque counts as the historical stand-
ard of truth of amyloid burden. The criteria for subject
selection in such studies is critical; selection of advanced
dementia subjects and a group of subjects with preserved
cognition will tend to give subject sets that are at the
extreme ends of the β-amyloid spectrum (neuritic plaque
densities of none or frequent by CERAD criteria [43]),
biasing towards finding high test sensitivity and specificity.
On the other hand, the likely beneficiaries of β-amyloid
PET imaging would be those in early disease development
with borderline β-amyloid pathology (sparse or moderate
plaque densities by CERAD criteria). Such subjects may
be most appropriate for trials testing disease-modifying
drugs because they are more likely to respond to avail-
able treatments. Subjects with a limited life expectancy
unrelated to cognitive status (e.g., elderly oncology pa-
tients) may have intermediate AD pathology, as well as
preserved cognition.
In the recently reported [18F]flutemetamol multicentre
end-of-life β-amyloid imaging trials [14, 49], subjects
were drawn from both dementia clinics and hospice
centres. While visual PET image assessments were com-
pared to neuritic plaque burden to demonstrate efficacy
for regulatory approval, neuropathology diagnoses and
multiregional histometric measures were also recorded
including amyloid plaque assessment by immunohisto-
chemistry and amyloid phase analysis. Rather than a
dichotomous distribution consisting mainly of pathology
extremes, the 106 subjects in this study represent a
broad and continuous spectrum of β-amyloid pathology,
as well as coincident neuropathology. This enabled
assessment of subjects with cortical β-amyloid burdens
that were borderline for clinicopathological significance,
associated with diffuse or neuritic plaques as well as the
effect of mixed pathology which is the subject of the
present study.
Materials and methods
Ethics, consent and permissions and consent to publish
This was a phase 3 multicenter PET study of flutemeta-
mol injection labelled with radioactive fluorine 18
([18F]flutemetamol) for detecting brain Aβ.
Institutional review boards or ethics committees at
the following institutions approved the study protocol
before initiation: St Margaret’s Hospital and Moorgreen
Hospital (Hammersmith, Queen Charlotte's & Chelsea
Research Ethics Committee); University of Michigan (The
University of Michigan Medical School Institutional
Review Board); Banner Alzheimer’s Institute, Banner Sun
Health Research Institute, Premier Research Institute,
Miami Jewish Health Systems, Galiz Research, VERITAS
Research, LasVegas Radiology, Memory Enhancement
Center and Compass Research (Western Institutional
Review Board); Mt Sinai Medical Center, Wien Center for
Alzheimer’s Disease, (Mount Sinai Medical Center);
Michigan State University (Michigan State University,
Biomedical and Health Institutional Review Board);
Barrows Neurological Institute (St. Joseph's Hospital &
Medical Center); Warren Alpert Medical School of Brown
University (Lifespan Research Protection Office, RI, USA).
All participants or their legal representatives provided
prior written informed consent including agreement to
publish subject to anonymization.
Trial subjects
Subjects with cognitive status ranging from normal to
advanced dementia and with a life expectancy of
12 months or less were enrolled at 16 centres in the
United States and the United Kingdom. Of 180 enrolled
subjects who were given [18F]flutemetamol, 69 died
within 13 months of imaging (Study GE067-007 [14]).
Sixty-eight brains were evaluable for a) neuritic plaque
assessment, b) correlation analysis between β-amyloid
immunohistochemistry (IHC) and [18F]flutemetamol
standardised uptake value ratio (SUVR) values, and c)
neuropathology diagnoses. Additional deaths occurring
after this time period but prior to July 2013 allowed a
further 39 evaluable brains to be included in a re-read
trial (Study GE067-026). One subject in GE067-007, who
died shortly after an accidental fall, underwent a Medical
Examiner’s autopsy, and this precluded regional mapping
for the primary objectives. One GE067-026 brain was
excluded as it was frozen rather than fixed at the site
neuropathology laboratory. A total of 106 subjects were
analysed in this study.
Procedures
Tissue processing and sampling
The whole brain was removed at autopsy, with brain
stem and cerebellum attached, and the two cerebral
hemispheres were separated. The entire left hemisphere
was immersion fixed in 10% neutral buffered formalin
for 21 days prior to transport. Dissection, sampling,
macroscopic photography and examination, histological
processing and staining were performed at a single
central laboratory (Covance Laboratories Ltd, Harrogate
UK) to minimize processing variability. Upon receipt of
the fixed hemisphere, the brain stem and hindbrain were
removed by transverse section of the midbrain at the
level of the third cranial nerve, and the hemisphere was
cut into 1-cm coronal slices. Eight neocortical regions
were sampled; the middle frontal gyrus, superior tem-
poral gyrus, middle temporal gyrus, and inferior parietal
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lobe from the lateral cerebral surfaces (these regions are
required by the Consortium to Establish a Registry for
Alzheimer's Disease [CERAD] [43]) and the anterior
cingulate gyrus, posterior cingulate gyri, precuneus, and
primary visual cortex from the medial surface. Two 3-mm
thick tissue blocks from the anterior and posterior surface
of each 1-cm thick cortical sample were embedded in
paraffin. Eleven additional paraffin tissue blocks were pre-
pared to enable neuropathology diagnostics; i) olfactory
tract and bulb, ii) striatum, iii) cholinergic basal forebrain
nucleus, iv) thalamus, v) medulla, vi) pre- and post-central
gyri, vii) anterior hippocampus, amygdala and entorhinal
cortex, viii) hippocampal body, ix) pons, x) midbrain, and
xi) cerebellum. The neuropathology diagnostic slide set
consisted of sections from the eight cortical regions and
the eleven additional regions; nineteen regions in total.
Histological analysis of the neocortical regions was
restricted to the left hemisphere, as the right hemisphere
was sometimes retained frozen for biochemical analysis
and was not always available. Prior evidence indicated that
β-amyloid pathology is typically symmetric in AD [44].
Three sections each separated by approximately 100 μm
were taken from both the anterior and posterior tissue
blocks from each neocortical region.
Neuritic plaque assessment
The scoring of neuritic plaque density has been a standard
part of AD neuropathology since 1991 Mirra et al. [33]
and through two iterations of recommended guidelines
Hyman et al. [26], Hyman et al. [25] and were therefore
deemed the most appropriate measure as the standard of
truth to demonstrate efficacy for market authorisation
regulatory approval when the GE067-007 Clinical trial was
initiated and for other amyloid PET tracers [11, 12, 14]. In-
deed, the regulatory authorities required the neuritic pla-
ques assessment as described by Mirra et al. [43].
However, it is recognised that neuritic plaques are identi-
fied by dystrophic neurites (Tauopathy) to which an amyl-
oid tracer is not expected to bind and that amyloid PET
tracers bind to the amyloid component in the neuritic
plaques.
Bielschowsky silver staining [39] was pre-validated
from standard techniques as the primary a priori
histopathology standard of truth (SOT) for the pres-
ence of clinically significant cortical β-amyloid. The
potential for inter-subject variation in staining was
mitigated by centralising the staining at a single la-
boratory, including appropriate quality controls and
recording staining quality on case report forms. For all
subjects, Bielschowsky-stained slides were assessed
semiquantitatively for neuritic plaque frequency in
neocortical regions using published CERAD-based
protocols; this methodology supports the subject-level
rating for neuritic plaque density determined by the
highest density (none, sparse, moderate or frequent)
found in any 10x objective field and in any neocortical
region examined [43]. While the use of this SOT may
be suitable for supporting a diagnosis of AD, other
SOTs may be more suited for comparison to a more
quantitative PET study. Accordingly, the classification
of each case as normal or abnormal was determined
by two additional methods (see Table 1), using mul-
tiple measures of neuritic plaque density in multiple
regions. Multiple assessments mitigated focal hetero-
geneity that would be evident microscopically but not
macroscopically at the lower (6-mm) resolution of
PET imaging. The 2 multi-measure methods were
both modified from CERAD and differed mainly in the
number of regions assessed. The first of these modi-
fied assessments averaged numeric assessments (arith-
metic mean - see below) of neuritic plaque density in
each of the 8 neocortical regions to give a continuous
variable. This method was aligned to the global
cortical PET assessment regions and formed our
Standard of Truth (mCERADSOT). The second method
limited the assessment to only those regions originally
recommended by CERAD and retained the categorical
assignation of ‘none’, ‘sparse’, ‘moderate’, or ‘frequent’
by employing the mode to average multiple categorical
scores within regions (mCERADmode), thus achieving a
score more representative of the total area instead of
being biased towards focal accumulations of plaques.
For the two modified CERAD assessments, a total of 30
measures per cortical region were recorded on case report
forms by neuropathologists (JI and CS). Briefly, 5 ran-
domly selected grey-matter fields of view per section were
Table 1 Bielschowsky assessments of neuritic plaque densities
Algorithm mCERADSOT mCERADmode CERAD
Regions assessed MFL, MTG, STG, IPL, ACG, PCG, PRC, PVC MFL, MTG, STG, IPL MFL, MTG, STG, IPL
Regional assessments 8 regional averages (mean) of 30
intra-regional numerica assessments
(each 0≤ x≤ 3)
4 regional averages (mode) of 30
intra-regional categorical assessments
(none, sparse, moderate, frequent)
1 global assessment from region of
highest involvement (none, sparse,
moderate, frequent)
Case dichotomy Any region >1.5 is abnormal Any region =moderate or frequent is abnormal moderate or frequent is abnormal
MFL midfrontal lobe, MTG middle temporal gyrus, STG superior temporal gyrus, IPL inferior parietal lobe, ACG anterior cingulate gyrus, PCG posterior cingulate
gyrus, PRC Precuneus, PVC primary visual cortex
aEach assessment was recorded as 0 = none (no plaques per 100x field of view), 1 = sparse (1-5 plaques), 2 = moderate (6-19 plaques) or 3 = frequent
(20 or more plaques). A total of 240 cortical assessments were recorded for each case
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assessed and neuritic plaque densities were recorded
as a score of 0 = none (no plaques), 1 = sparse (1–5 pla-
ques), 2 =moderate (6–19 plaques), and 3 = frequent
(20+ plaques per 100x field of view [FoV]). [43, 60] For
mCERADSOT, 8 regional scores were calculated as the
arithmetic mean of the 30 measures per region. The
scale midpoint was 1.5, representing the threshold be-
tween sparse and moderate categories; a mean score
≤1.5 was considered normal while a mean score of
>1.5 was considered abnormal for each region. The di-
chotomous classification of the whole brain as β-
amyloid normal or abnormal was aligned to the
CERAD principle of the region of maximal involve-
ment: if any one of the 8 regions was considered
abnormal, i.e., any regional mCERADSOT was > 1.5, the
whole brain was considered abnormal. Conversely,
only if all regions were considered normal (≤1.5) was
the brain considered β-amyloid normal (see Table 1).
The dichotomy of the brain as normal or abnormal
was used for sensistivity and specificity calculations
mandated as an endpoint for the trial whereas the
continuous variable mCERADSOT provided a less
discrete measure to compare to SUVR.
For mCERADmode, the 30 measures made in each re-
gion (middle frontal, superior and middle temporal, and
inferior parietal regions only) were averaged using mode
to provide 4 regional categorical measures of none,
sparse, moderate, or frequent. The brain was then
dichotomised as abnormal if any region had a categorical
assessment of moderate or frequent (see Table 1).
All measures were performed at a single laboratory to
ensure consistency within the cohort as a consensus by
two neuropathologists (JI and CS) against a priori cri-
teria and blinded to clinical and imaging data and to the
results of other histopathology analyses.
β-amyloid immunohistochemistry
Immunohistochemistry for β-amyloid was a secondary
reference standard used for two sets of analyses (correl-
ation with PET tracer retention measurements and
neuropathology diagnoses). β-amyloid IHC (monoclonal
antibody, clone 4G8; SIG-39220, Covance, USA, diluted
1:100) was performed on 5 μm sections after 88% (v/v)
formic acid pre-treatment for 5 min and heat-mediated
antigen retrieval and detected using biotinylated second-
ary antibody (DakoCytomation E0354, UK) and DAB-
Map Kit (Ventana, USA). Staining was pre-validated and
standardized on an automated Ventana Discovery XT
staining module.
In the first 30 brains analysed, the percentage of grey-
matter area stained by the monoclonal antibody 4G8
was used for correlation analysis with regional PET
SUVR measures. This analysis was performed on 3 step
sections (separated by 100 μm) from the anterior block
of each cortical region. For each of 5 randomly selected
grey matter 100x fields of view per section, automated
histometric measures of the % area of β-amyloid in 4G8-
stained sections were recorded. A mean value was deter-
mined for each cortical region. Stained sections were
imaged using whole slide scanning (Aperio XT) with a
pre-developed and validated macro (MATLAB; Math-
Works Inc, MA, USA) used to threshold intensity, size,
and morphometry after colour deconvolution to remove
the haematoxylin staining channel. All histometric mea-
sures were performed at a single laboratory to ensure
consistency within the cohort by individuals who were
blinded to clinical and imaging data and to the results of
other histopathology analyses.
Neuropathology diagnoses
For central laboratory neuropathological diagnosis, sin-
gle sections from each of the 8 cortical regions and 11
additional neuropathology regions listed above were
stained with haematoxylin and eosin, Bielschowsky silver
(as above), β-amyloid IHC (as above), and Tau IHC
(monoclonal antibody AT8; Cat No. MN1020, Thermo
Scientific, UK). Additional sections from the entorhinal
cortex and midbrain were stained for α-synuclein (mono-
clonal antibody; NCL-L-ASYN, Leica Microsystems, U.K.)
to assess Lewy body pathology, and ubiquitin (polyclonal
antibody; Z0458, DakoCytomation, UK). Neuropathology
reports were prepared, including macroscopic observa-
tions, microscopic findings and relevant interpretive diag-
noses. Braak staging of neurofibrillary tangles (NFT) [8],
CERAD scoring of neuritic plaque frequency [43], β-
amyloid phase analysis [58], and AD likelihood according
to the National Institute of Aging-Reagan Institute (NIA-
RI) diagnostic criteria [26] were recorded on case report
forms. Where additional analyses were reported by the re-
ferring sites (e.g. TDP-43 immunopositivity), these were
transferred to the case report forms. Neuropathology diag-
noses were made at a single centre by two neuropatholo-
gists (AC and AI) to ensure consistency across the cohort.
A diagnosis of AD was made according to the National In-
stitutes of Ageing – Reagan Institute criteria [9]. Both
neuropathologists were blinded to clinical and imaging
data and to the results of cortical neuritic plaque analyses.
Because of blinding to clinical data, neuropathology diag-
noses were made with the assumption of dementia. AD
neuropathologic changes were also categorised post-hoc
according to the more recent NIA-Alzheimer’s Associ-
ation criteria (NIA-AA) [25] using amyloid phase [58],
Braak NFT stage and CERAD neuritic plaque score,
collected above, as these criteria were published after trial
initiation. Cerebral amyloid angiopathy (CAA) was cate-
gorised by Vonsattel grade, stage and type [57]. Other
diagnoses were made against the following criteria; Tangle
predominant dementia [68, 29], frontotemporal lobar
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degeneration (Picks Disease) [29], dementia with Lewy
bodies [42], multiple system atrophy [22], and progressive
supranuclear palsy [23, 40]. It should be noted that subse-
quent to the trial additional guidelines and diagnostic cri-
teria for AD [25] and primary age-related tauopathy [13]
have been published.
PET imaging and analysis
The acquisition of [18F]flutemetamol PET images and
analysis are described in detail elsewhere [14]. Briefly,
Flutemetamol F 18 Injection was administered intraven-
ously at a dose of 185-370 MBq of radioactivity at phys-
ician discretion, based on how long a scan the patient
could be anticipated to tolerate; scan times were ad-
justed to dose to ensure equivalent scan quality with
minimal patient discomfort. PET images were acquired
in 2-min frames on PET/computerized tomography
(CT) scanners, beginning approximately 90 min post
injection. Typically, for an injected activity of 370 MBq,
five 2-min frames were summed to give a 10-min scan,
which was attenuation-corrected using CT data. Most
images were reconstructed iteratively to form axial slices
of 128 X 128 pixels and with ~90 slices covering the en-
tire cerebrum. Image reconstructions were optimised at
each PET centre using a NEMA IEC phantom [46] prior
to patient imaging. In addition, a CT-scan was acquired.
Equipment used to capture images varied across the
study sites. The images were evaluated overall as either
positive (abnormal/pathological) or negative (normal)
for fibrillar β-amyloid in a blinded image evaluation
(BIE) by 5 independent image readers who were blinded
to all clinical, demographic, and pathology information.
Readers were trained independently using GE Health-
care’s automated reader training program [17, 54, 63].
The interactive training program gave instruction on
brain anatomy, image display, and assessment method-
ology to classify 5 regions; frontal lobe, lateral temporal
lobe, parietal lobe, posterior cingulate/precuneus, and
the striatum as either normal or abnormal. Following
the training, readers had to pass a test in which they had
to correctly classify at least 14 out of 15 test cases as
normal or abnormal. Five trained readers classified the
study cases as normal or abnormal using the same read-
ing and classifying methodology. If any one of the
regions assessed in a given case image was deemed to be
abnormal, the case was dichotomised as a positive image
assessment [49]. The confidence with which a reader
was able to reach the decision made was recorded on a
scale of 1–5 (5 being most confident). The majority read
for each subject’s PET image is defined as the image
interpretation (normal/abnormal) made by at least 3 of
the 5 readers. BIE analysis of the first 68 subjects (Study
GE067-007) by 5 different readers from those used in
GE067-026 are presented elsewhere [14] and are not
part of this post-hoc analysis. It should be noted that
PET assessments in this study was based solely upon
image assessment by readers, and that SUVR measures
(see below) were not used for primary dichotomous
assessment as normal or abnormal.
Mapping histopathology measures to quantitative PET
image SUVR measures
A detailed mapping regimen was implemented for the
first 30 brains to co-register SUVR measurements with
the 8 neocortical samples. SUVRs were measures of neo-
cortical PET tracer retention normalised to the retention
in the relatively spared cerebellum (SUVRcer) or pons
(SUVRpon). Individual regional values were recorded and
a composite SUVR (average across the 8 neocortical
regions) was calculated. These measures were used as a
pre-planned analysis to correlate tracer retention with β-
amyloid histopathology as continuous rather than dichot-
omised variables. In addition to the first 30 brains, 2
further brains were added to this analysis post-hoc to
understand the underlying pathology of false positives
(cases 29 and 43 in Table 2). Photographs of the left hemi-
spheres were taken pre- and post-sampling during the
recording of macroscopic observations by the neuro-
pathologist and during dissection of the fixed brains
(Additional file 1). These included reconstructed hemi-
spheres post-sampling to record the precise anatomical
location from which the histological measures were
made. These images were uploaded to the trial image
repository and used to identify the regions sampled on
ante-mortem anatomic images (CT or MRI) allowing
registration with the PET images and enabling the rele-
vant volumes of interest (VOIs) to be identified and to
determine the regional SUVR. To ensure consistency
across all subjects, this mapping was performed by a
single individual (KH) who was blinded to clinical data
and histopathology.
Data collection and analysis
All data were collected from the clinical, imaging and
pathology analysis centres via case report forms, which
were quality-controlled before being transferred to a
central data management centre (i3 Statprobe, Austin,
Texas, USA, for trial GE067-007 and H2O Clinical LLC,
Hunt Valley, Maryland, USA for GE067-026). Pathology
data from the initial 68 brains in trial GE067-007 were
used verbatim for the extended GE067-026 trial and no
reanalysis was performed on these brains. All data blinds
were maintained until the database was locked, at which
point the data for the study primary objectives were
analysed. The study GE067-026 [49] met its pre-defined
success criteria of the lower bound of the 95% exact bi-
nomial confidence interval exceeding 75% for sensitivity
and 60% for specificity for the majority interpretation.
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Table 2 Subject demographic information and data
Demographics Neuropathology Imaging
Case Age Sex Timea Dementiab mCsc Aβd ADe CERADf Braakg Amyloid phaseh Diagnosesi SUVRj PETmajk
1 73 F 360 Yes 0.0 n.d. Normal - II 1 Inf TDPl 1.13 Normal
2 84 M 17 Yes 0.0 0.3 Normal - I 0 Normal 1.18 Normal
3 83 M 568 No 0.0 n.d. Normal - IV 1 LBD 1.17 Normal
4 91 M 130 Yes 0.0 0.9 Normal - 0 0 PSP VAD 1.34 Normal
5 63 M 433 No 0.0 n.d. Low - II 1 PSP 1.42 Normal
6 76 F 145 Yes 0.0 n.d. Normal - II 1 LBD VAD 1.22 Normal
7 70 M 16 No 0.0 n.d. Normal - 0 0 Normal 1.44 Normal
8 67 M 32 No 0.0 n.d. Normal - I 0 Normal 1.37 Normal
9 80 M 131 Yes 0.0 n.d. NA - III 0 TPD 1.26 Normal
10 61 F 34 No 0.0 n.d. Normal - 0 1 Normal 1.67 Normal
11 65 F 393 No 0.0 n.d. Normal - III 1 AC 1.21 Normal
12 60 M 374 No 0.0 n.d. Low - III 1 VAD 1.34 Normal
13 74 M 170 Yes 0.1 8.1 Normal - 0 2 VAD 1.12 Normal
14 66 M 155 No 0.1 n.d. Normal - 0 0 AC 1.3 Normal
15 76 F 10 Yes 0.1 0.2 Normal - I 2 Normal 1.56 Normal
16 63 M 12 No 0.1 n.d. Normal - 0 0 Normal 1.6 Normal
17 73 F 105 Yes 0.5 0.4 Normal - V 1 TPD 1.34 Normal
18 90 F 115 Yes 0.0 n.d. Low S III 1 Inf AS 1.4 Normal
19 89 F 78 No 0.3 n.d. Int S IV 2 CAA AD 1.25 Normal
20 82 F 24 Yes 0.4 0 Low S III 1 LBD 1.72 Normal
21 92 F 210 Yes 0.7 n.d. Normal S II 4 CAA PD 1.55 Normal
22 84 F 69 Yes 1.1 1 Int S II 2 Inf 1.36 Normal
23 72 M 142 Yes 1.3 n.d. Normal S 0 3 FTD 1.01 Normal
24 87 F 76 Yes 1.4 2 Low S I 3 VAD 1.57 Normal
25 87 F 137 Yes 1.5 n.d. Normal S 0 2 AC AS 1.53 Normal
26 60 M 11 Yes 1.7 n.d. Low S II 4 CAA 1.08 Normal
27 81 M 189 No 1.8 n.d. Normal S I 4 ND 1.6 Normal
28 92 F 212 Yes 2.1 n.d. Int S III 3 TDPl 1.26 Normal
29 87 F 131 Yes 1.4 8.1 Low S IV 5 LBD 1.95 Abnormal
30 96 F 630 Yes 1.9 n.d. High S VI 5 AD 2.15 Abnormal
31 92 F 132 Yes 1.9 n.d. Low S III 4 LBD 2.72 Abnormal
32 89 F 311 Yes 2.0 n.d. Int S III 5 AD CAA VAD 2.33 Abnormal
33 88 F 118 Yes 2.1 n.d. Low S II 4 Inf LBD AS 3.14 Abnormal
34 80 M 2 Yes 2.1 7.6 High S VI 5 AD LBD 2.1 Abnormal
35 94 F 19 Yes 2.1 7.7 Int S III 5 AD 1.95 Abnormal
36 88 F 329 Yes 2.1 n.d. High S V 5 AD 2.84 Abnormal
37 74 F 550 Yes 2.8 n.d. High S VI 5 AD 2.23 Abnormal
38 86 M 19 No 1.4 2.3 Int M III 3 AD 1.45 Normal
39 75 M 64 Yes 1.4 1.4 Int M II 3 Inf LBD 1.23 Normal
40 84 M 349 Yes 1.6 n.d. Int M V 3 AD LBD AS VAD Ath 1.73 Normal
41 93 M 323 No 1.9 n.d. Low M II 3 LBD 1.36 Normal
42 87 M 22 No 2.7 4 Int M IV 4 AD 2.04 Normal
43 86 F 193 Yes 0.3 9.4 Low M III 4 LBD 2.07 Abnormal
Ikonomovic et al. Acta Neuropathologica Communications  (2016) 4:130 Page 6 of 24
Table 2 Subject demographic information and data (Continued)
Demographics Neuropathology Imaging
Case Age Sex Timea Dementiab mCsc Aβd ADe CERADf Braakg Amyloid phaseh Diagnosesi SUVRj PETmajk
44 76 M 84 Yes 1.5 10.3 Low M II 3 LBD 1.87 Abnormal
45 75 M 373 Yes 1.6 n.d. Int M IV 5 AD CAA 1.48 Abnormal
46 82 F 127 Yes 1.7 n.d. Int M IV 4 AD LBD 2.32 Abnormal
47 86 M 395 Yes 1.8 n.d. High M V 5 AD 2.83 Abnormal
48 93 F 500 Yes 1.8 n.d. Int M V 3 AD AS VAD 1.6 Abnormal
49 84 M 45 Yes 1.8 n.d. Low M II 3 VAD 1.85 Abnormal
50 93 F 243 Yes 1.9 n.d. High M VI 5 AD 2.72 Abnormal
51 93 F 755 Yes 2.0 n.d. High M IV 5 AD 2.2 Abnormal
52 80 M 276 Yes 2.0 n.d. High M VI 4 AD 2.33 Abnormal
53 90 M 308 Yes 2.1 n.d. Low M II 4 LBD 2.19 Abnormal
54 78 M 62 Yes 2.1 10.1 High M VI 5 AD LBD 2.86 Abnormal
55 86 F 747 Yes 2.1 n.d. Int M IV 3 AD CAA 1.81 Abnormal
56 73 F 295 No 2.2 n.d. Low M I 3 LBD 1.76 Abnormal
57 87 F 318 Yes 2.2 n.d. Int M III 5 AD AS VAD Ath 2.26 Abnormal
58 88 F 266 Yes 2.2 n.d. Int M III 4 AD LBD 1.91 Abnormal
59 88 F 79 Yes 2.3 17.6 High M VI 5 AD 1.67 Abnormal
60 93 F 396 Yes 2.3 n.d. High M VI 5 AD CAA Inf 3.08 Abnormal
61 85 M 60 No 2.4 14.7 High M VI 5 CAA AD VAD 2.81 Abnormal
62 91 M 30 Yes 2.4 2.9 High M V 4 AD 1.86 Abnormal
63 95 F 15 Yes 2.4 7.5 High M VI 5 AD 1.89 Abnormal
64 79 M 42 No 2.4 n.d. Int M III 4 CAA mCa AD 2.44 Abnormal
65 81 F 184 Yes 2.5 n.d. Int M IV 3 LBD 1.66 Abnormal
66 84 F 193 Yes 2.6 n.d. High M V 5 AD 2.4 Abnormal
67 72 M 268 Yes 2.7 n.d. High M VI 5 AD VAD 2.07 Abnormal
68 63 M 342 Yes 2.8 n.d. High M VI 5 AD AS VAD 1.94 Abnormal
69 89 F 115 Yes 3.0 n.d. High M VI 5 AD CAA LBD AS 2.39 Abnormal
70 83 F 611 Yes 1.8 n.d. Low F I 4 AS CAA VAD TDPl 1.87 Normal
71 84 F 189 No 1.7 n.d. Int F 0 3 CAA Inf VAD AD 2.02 Abnormal
72 82 M 397 Yes 1.9 n.d. High F VI 5 AD CAA VAD 2.41 Abnormal
73 86 F 155 Yes 2.0 n.d. High F V 5 AD 2.43 Abnormal
74 93 F 594 Yes 2.0 n.d. High F IV 5 AD 2.46 Abnormal
75 90 F 538 Yes 2.0 n.d. High F VI 4 AD CAA AS VAD 2.78 Abnormal
76 78 F 180 Yes 2.2 n.d. Normal F 0 4 MSA 2.03 Abnormal
77 93 F 200 Yes 2.2 n.d. High F V 5 AD AS CAA LBD VAD 2.42 Abnormal
78 78 F 125 Yes 2.2 n.d. High F VI 5 AD LBD 2.12 Abnormal
79 72 M 1 Yes 2.4 11.4 High F VI 5 AD 2.37 Abnormal
80 76 F 27 Yes 2.4 n.d. High F VI 5 AD CAA 1.83 Abnormal
81 77 F 11 Yes 2.4 8.9 High F VI 4 AD 1.59 Abnormal
82 91 F 55 Yes 2.4 11.2 High F VI 4 AD CAA 2.2 Abnormal
83 81 M 204 Yes 2.4 n.d. High F VI 4 AD CAA LBD 2.41 Abnormal
84 82 M 15 Yes 2.5 6.9 High F VI 4 AD CAA 2.23 Abnormal
85 83 M 34 Yes 2.5 8.5 High F VI 5 AD 2.6 Abnormal
86 90 F 51 Yes 2.5 12.2 High F VI 4 AD 2.35 Abnormal
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All analyses presented here represent post-hoc analyses
of pathology data collected during the clinical trials
GE067-007 (N = 68) and GE067-026 (N = 106), regional
co-registered histopathology correlates and SUVRs
collected in a subset (N = 32) of the GE067-007 subjects,
and PET image evaluation by 5 independent readers of
all 106 subjects read as a single trial GE067-026.
Receiver operating characteristic (ROC) analysis was used
to determine optimal threshold values for the post-hoc
analysis of regional mCERADSOT, β-amyloid IHC % area
measures, and for SUVR thresholds. SUVR comparisons
were performed using parametric analysis of variance
(ANOVA). The Fleiss coefficient Pi was used to measure
inter-reader agreement [Pi = 1/n(n-1)*(A
2 +N2-n), where n
is the number of readers, A is the number calling the case
abnormal, and N is the number of readers calling the case
negative] [18]. Non-parametric tests for correlation (Spear-
man’s), differences (Wilcoxon Rank Sum Test or Mann-
Whitney U test, Kruskal-Wallis test), and contingency ana-
lysis (χ2 and Fisher’s Exact Test) were used for all other
analyses where indicated. All statistical tests were per-
formed using StatSoft Statistica software (Tulsa, USA)
unless otherwise stated. All graphs and figures (Except
Figs. 1 and 3) were also produced using Statistica software.
Graphical representation in box plots represent mean +/- 1
standard error (SE, boxes) and 95% confidence intervals
Table 2 Subject demographic information and data (Continued)
Demographics Neuropathology Imaging
Case Age Sex Timea Dementiab mCsc Aβd ADe CERADf Braakg Amyloid phaseh Diagnosesi SUVRj PETmajk
87 73 F 27 Yes 2.5 9.6 High F VI 5 AD 2.23 Abnormal
88 87 M 1 Yes 2.5 7.8 High F IV 4 AD CAA 2.1 Abnormal
89 89 F 768 Yes 2.5 n.d. High F V 5 AD CAA LBD AS 1.93 Abnormal
90 79 M 332 Yes 2.5 n.d. High F VI 5 AD CAA LBD 2.24 Abnormal
91 80 M 0 Yes 2.6 7.9 High F VI 5 AD 2 Abnormal
92 79 F 422 Yes 2.6 n.d. High F V 5 AD CAA LBD AS VAD HC 2.38 Abnormal
93 87 M 106 Yes 2.6 n.d. High F VI 5 AD 2.2 Abnormal
94 66 F 139 Yes 2.7 n.d. High F VI 5 AD 2.37 Abnormal
95 84 M 181 Yes 2.7 n.d. High F V 4 AD LBD 2.75 Abnormal
96 87 M 769 Yes 2.7 n.d. High F VI 5 AD CAA LBD VAD 2.5 Abnormal
97 71 M 305 Yes 2.7 n.d. High F V 5 AD CAA 2.47 Abnormal
98 72 F 565 Yes 2.7 n.d. High F VI 5 AD CAA LBD 2.58 Abnormal
99 85 M 846 Yes 2.8 n.d. High F VI 5 AD VAD 2.01 Abnormal
100 84 F 198 Yes 2.8 6.3 High F VI 4 AD 1.48 Abnormal
101 85 F 436 Yes 2.9 n.d. High F VI 5 AD 2.65 Abnormal
102 75 F 66 Yes 2.9 10.6 High F VI 5 AD 2.47 Abnormal
103 87 M 493 No 2.9 n.d. High F IV 5 CAA LBD AD 2.42 Abnormal
104 86 F 127 Yes 3.0 n.d. High F VI 5 AD 2.9 Abnormal
105 81 M 171 Yes 3.0 n.d. High F VI 5 AD 2.34 Abnormal
106 63 M 562 Yes 3.0 n.d. High F VI 5 AD 2.72 Abnormal
Subjects are ranked by CERAD neuritic plaque frequency and then by mCERADSOT. AC ageing changes, AD Alzheimer’s disease (high or intermediate
likelihood by National Institute of Ageing-Reagan Institute criteria), AS arteriosclerosis or arteriolosclerosis, Ath atherosclerosis, CAA cerebral amyloid
angiopathy, FTD frontotemporal lobar degeneration, HC hydrocephalus, Inf infarct, LBD Lewy body disease, mCa metastatic carcinoma, MSA multisystem
atrophy, ND neurofibrillary degeneration, PD Parkinson’s disease, PSP progressive supranuclear palsy, SUVR standard retention value ratio, TDP+ TDP43
immunopositivity, TPD tangle-predominant dementia, VSD vascular disease not otherwise specified
aTime between PET imaging and death in days
bDementia recorded in the study medical history
cmCERADSOT; maximal regional mean score determining Standard of Truth assignation as abnormal if > 1.5
dPercentage area of grey matter stained positively by amyloid β immunohistochemistry (4G8) determined only on a subset (32 subjects) of the cohort
eAlzheimer’s Disease likelihood recorded by a neuropathologist against National Institute of Ageing-Reagan Institute criteria [26] but blinded to dementia status
fCERAD neuritic plaque frequency recorded during neuropathology diagnoses (N: none; S: sparse; M: moderate; F: frequent)
gBraak neurofibrillary tangle stage recorded during neuropathology diagnosis
hAmyloid phase [25, 58]
iNeuropathologist’s diagnoses blinded to clinical data. Note: co-incident plaque burden may be present in non-AD diagnoses
jComposite SUVR determined from bilateral measures and normalised to cerebellum as the reference region
kMajority PET image evaluation
lTDP43 immunopositivity was recorded at the site neuropathology laboratories, not as part of the diagnoses for the GE studies. This analysis was not performed
on all subjects
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(whiskers). Outlier and extreme values are presented as
open circles and asterisks, respectively and are identified by
the Statistica software as; outlier values >UBV+ o.c.*(UBV-
LBV) OR <LBV - o.c.*(UBV • LBV); extreme values >UBV
+ 2*o.c.*(UBV-LBV) OR <LBV - 2* o.c.*(UBV • LBV) where
UBV is the upper box value (mean + 1SE), LBV is the lower
box value (mean-1SE) and o.c. is the outlier coefficient set at
1.5. Note for probability plots (Figs. 2a–d, 6c and 7b, d & e)
all values are either 0 or 1 and extreme and outlier values
will always be 0 or 1. For confidence plots (Figs. 4c and 5b)
all values are integers between 1 and 5 and so all outlier and
extreme values will be integers. For inter-reader agreement
plots (Figs. 4a & b and 5a) Pi values are 1 (5/5 agreement),
0.6 (4:1 or 1:4 agreement) or 0.4 (3:2 or 2:3 agreement) and
all outlier and extreme values will have these values. For all
other plots outliers and extremes are continuous variables.
Results
The GE067-026 cohort of 106 brains included a broad
and continuous spectrum of β-amyloid pathology based
on mCERADSOT and CERAD assessments (Fig. 1a).
Seventy-six brains (72%) were determined to be
0
1.5
3
a
b
1 11 21 31 41 51 61 71 81 91 101
Subject ranked by maximum mCERADSOT from CERAD regions
Max all regions 
Max CERAD regions
Min CERAD regions
Min all regions
None Sparse Moderate Frequent
*
*
*
0
5
10
15
20
25
30
35
40
None Sparse Moderate Frequent
CERAD Neuritic plaque frequency
16% 19% 30% 35%
Fig. 1 The GE067-026 cohort contained a broad and continuous spectrum of neocortical neuritic plaque burden. Panel a. Subjects ranked by the
maximal mCERADSOT score for CERAD regions demonstrating a number of cases where dichotomy was based on a burden close to the threshold
of 1.5. (cases were determined to be abnormal if any regional score was greater than 1.5, i.e. if the upper ‘whiskers’ in the plot are over 1.5). Most
disparities between pathology and PET dichotomy as abnormal or normal occur in cases where the neuritic plaque mCERADSOT score is close to
the threshold. Downward arrowheads indicate abnormal cases that were assessed as normal by PET (false negatives) and asterisks indicate normal
cases assessed as abnormal (false positives). Panel b. The spread of cases categorised by CERAD neuritic plaque frequency
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abnormal by mCERADSOT, and 30 (28%) were assessed
as normal; together, these brains provided a continuous
distribution of cases throughout the range of neuritic
plaque pathology (Fig. 1b). Demographic data, path-
ology, and majority PET BIE assessments for all subjects
are given in Table 2. Sixty-six cases had a neuropatho-
logical diagnosis of AD (62%), defined as either ‘inter-
mediate’ or ‘high’ likelihood by NIA-RI criteria [26], in
which neuritic plaques are nominally moderate or fre-
quent in the neocortex. While AD was the predomin-
ant neuropathological diagnosis (Table 3), it was often
recorded with coincident pathologies, such as CAA
(n = 24) or other vascular disease (n = 27), or Lewy
body disease (LBD, n = 16). Just less than half of the
66 AD cases had “pure” AD (n = 30). Lewy body dis-
ease was the next most predominant diagnosis (n =
29; 27%) and, in addition to the 16 cases with coinci-
dent AD pathology sufficient for a diagnosis of AD,
many other cases had varying degrees of co-incident
β-amyloid neuropathology (Table 2). Indeed, many of
the subjects without a primary diagnosis of AD had a
range of coincident AD pathology, potentially allowing
assessment of PET imaging in a target population
where underlying AD pathology may be coincident
with other dementing disorders. This mixed pathology
population included cases with neuritic plaque fre-
quencies close to the dichotomous threshold, i.e.
between sparse (normal) and moderate (abnormal)
which was the presumed a priori lower limit of
plaque burden detectable with [18F]flutemetamol.
Subjects classified as abnormal by mCERADSOT were
generally older than those categorised as normal (P <
0.01, Mann-Whitney) and the average age of female
subjects was slightly older than that of males (81.5 vs
78.5 years respectively; P < 0.001 Mann-Whitney).
mCERADSOT was independent of gender (P = 0.57
Mann-Whitney). Most histometric measures of pla-
ques, tangles, and diagnoses were correlated (Table 4),
as would be expected, given that the diagnoses of AD
were derived from these measures.
Time between PET scan and death did not signifi-
cantly influence the outcome although we note that one
false negative case died 611 days after PET. While it is
possible that the amyloid burden increased during this
period we are unable to confirm this.
Blinded image evaluations of PET Images
Seventy-two cases were assessed as positive (abnor-
mal) by majority read and the remaining 34 cases
were normal by majority read (Table 2). As β-amyloid
Fig. 2 The probability that the PET image is interpreted as positive increases with cortical neuritic plaque burden. Panel a. The probability (0-1) of
a PET positive assessment increases with CERAD neuritic plaque frequency (N = 106). Panel b. The probability of PET positive image assessment
by neocortical regional mCERADSOT score (N = 424, 4 neocortical regions per case; frontal, temporal, parietal and posterior cingulate/precuneus).
Panel c & d. The probability of PET positive image assessment increases by AD diagnosis against the NIA-AA (Panel c) and NIA-RI criteria (Panel d).
For all panels, boxes represent mean +/- 1 standard error and whiskers represent 95% confidence interval. Open circles represent outlier values
and asterisks represent extreme values (see Materials and methods for details)
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is believed to deposit in phases, starting with the neo-
cortex and advancing to subcortical regions [58], the
pattern of regional PET assessment was examined.
Only one case was classified as abnormal on the basis
of a single cortical region showing abnormal retention
(case 49). All other cases assessed as positive by ma-
jority were positive in more than one neocortical re-
gion. With respect to cortical versus striatal results
(with the potential to compare to β-amyloid phases
[58]), 6 cases were cortical positive and striatal nega-
tive (cases 44, 48, 49, 55, 58 and 64) and no case was
deemed majority positive solely on the basis of an ab-
normal striatal retention pattern. Of the 72 majority
BIE positive cases, 55 (76%) were abnormal in all 5
regions assessed and thus clearly positive. The poster-
ior cingulate/precuneus was deemed abnormal in all
cases positive by majority BIE. The striatum was
deemed abnormal in 66 of these 72 positive cases by
majority BIE.
The probability of the PET image being rated as ab-
normal increased with neocortical neuritic plaque fre-
quency and AD diagnosis (Fig. 2). Illustrations of PET
images alongside representative histopathology for select
case are shown in Fig. 3, including some cases with dis-
cordant pathology versus PET results, which are dis-
cussed later.
Reader confidence was higher in cases deemed ab-
normal by mCERADSOT than in those deemed β-
amyloid normal (P = 0.000125, Mann Whitney U test),
suggesting that readers felt more confident identifying
abnormal retention patterns than the normal white-
matter retention pattern. Unsurprisingly, reader confi-
dence was highest in highly abnormal cases i.e. CERAD
frequent or amyloid phase 5 cases (Fig. 4) and inter-
reader agreement was highest in cases that were either
clearly positive (phase 5/frequent) or negative (phase
0–2/none). When neocortical β-amyloid pathology was
close to the threshold (sparse/moderate or amyloid
phase 3) reader confidence and inter-reader agreement
worsened (Fig. 4). Readers were less confident assessing
cases that were subsequently classified as false nega-
tives compared to true negatives or true positives (P <
0.05 and P < 0.001 respectively Mann-Whitney U test)
and inter-reader agreement was also worse (Fig. 5; P <
Table 3 PET majority, AD and mCERADSOT assessment by disease category
Disease category Number Percent PETmaj abnormal # With coincident ADa # mCERADSOT abnormal
Alzheimer's Diseasea 66 (62%) 62 66 64
Lewy Body Diseaseb 29 (27%) 23 16 22
Cerebral Amyloid Angiopathyc 27 (25%) 23 24 25
Vasculard 21 (20%) 14 14 16
Arteriosclerosise 13 (12%) 9 9 11
Infarct 7 (7%) 3 2 3
Normal 6 (6%) 0 0 0
Ageing Changes 3 (3%) 0 0 0
TDP43 immunopositivef 3 (3%) 0 0 2
Tangle predominant dementia 2 (2%) 0 0 0
Progressive Supranuclear Palsy 2 (2%) 0 0 0
Atherosclerosis 2 (2%) 1 2 2
Frontotemporal Dementia 1 (1%) 0 0 0
Metastatic carcinoma 1 (1%) 1 1 1
Hydrocephalus 1 (1%) 1 1 1
Multiple system atrophy 1 (1%) 1 0 1
Neurofibrillary degeneration 1 (1%) 0 0 1
Parkinson's Disease 1 (1%) 0 0 0
AD Alzheimer’s disease, mCERADSOT standard of truth by modified Consortium to Establish a Registry for Alzheimer’s Disease criteria, N Number of subjects, PETmaj
majority read of positron emission tomography images, SOT standard of truth
All neuropathology diagnoses made blind to clinical data
aIncludes intermediate or high likelihood by National Institute of Ageing-Reagan Institute criteria irrespective of dementia status
bDiagnosed as dementia with Lewy bodies blinded to clinical data
cDoes not include focal cerebral amyloid angiopathy
dIncludes: multifocal infarcts, microinfarcts, cerebral vascular disease, vascular brain injury and vascular dementia
eincludes arteriosclerosis and arteriolosclerosis
fTDP43 immunopositivity was recorded at the site neuropathology laboratories, not as part of the diagnoses for the GE studies. This analysis was not performed
on all subjects
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0.001 Kruskal-Wallis). Despite the temporal cortex be-
ing the most involved of the cortical regions by path-
ology, the temporal cortex was scored as abnormal by
PET the least frequently of the cortical regions
assessed. Inter-reader agreement and probability of a
positive BIE assessment were lowest in the temporal
cortex and in the striatum, although these differences
did not reach statistical significance (Kruskal Wallis;
P > 0.05). Observed regional BIE assessments were
significantly different from those expected based upon
Fig. 3 PET images and representative histopathology for a range of subjects including some disparity cases (PET images are representative Rainbow
colour scale, axial and parasagittal slices. BIE status and results for the 5 readers (N = normal, A = abnormal). A representative photomicrograph of β-
amyloid IHC (frontal lobe) with % area (if determined), representative photomicrograph of Bielschowsky silver stain (frontal lobe) and Bielschowsky
score (original magnification 100x for both); Braak stage of neurofibrillary tangles and overall neuropathological diagnosis, including AD likelihood
(NIA-RI criteria). Note: the photomicrographs of the frontal lobe may not accurately represent the pathology of other regions
Fig. 4 Inter-reader agreement and reader confidence are decreased in cases with a plaque burden close to the threshold of PET detection. Panel
a shows inter-reader agreement across the spectrum of mCERADSOT scores with values lowest about the 1.5 threshold. The transition from
amyloid phase 2 to phase 3 is associated with neocortical plaque burden between sparse and moderate (see Fig. 4) and both inter-reader
agreement (Panel b) and reader confidence (Panel c) is lowest in phase 3 (P < 0.001 for both data sets, Kruskal Wallis test). Inter-reader agreement
was determined as Fleiss’ kappa coefficient Pi (see text for details) and for 5 readers is 1 when all 5 readers are in agreement, 0.6 when the
agreement is 4:1 and 0.4 when the agreement is split 3:2. Confidence was recorded as a 5 point scale (1–5) with 5 being most certain and 1
being the least certain. For all panels, boxes represent mean +/- 1 standard error and whiskers represent 95% confidence interval. Open circles
represent outlier values and asterisks represent extreme values (see Materials and methods for details)
Ikonomovic et al. Acta Neuropathologica Communications  (2016) 4:130 Page 13 of 24
the regional mCERADSOT scores (P = 0.0079; χ
2 test)
with the temporal lobe assessed as abnormal less fre-
quently than expected, and the other three cortical regions
scored as abnormal slightly more frequently than ex-
pected. Together, these results possibly reflect a slightly
more difficult interpretation of the temporal lobes com-
pared to the other regions because of the combination of
depth of sulci and partial volume effects.
Asymmetry was an occasional feature in the PET
images, but while there was a small potential to mis-
classify cases if the β-amyloid burden was above
threshold in the hemisphere not sampled for histo-
pathology assessment, asymmetry was usually focal
and no images showed asymmetry in all regions
assessed (global asymmetry). Furthermore, there were
very few cases dichotomized as abnormal by either
PET or pathology based on a single region (which
would be the cases most susceptible to misclassifica-
tion), and so the risk of misclassification appeared
small. Nevertheless, all cases where there was notable
asymmetry (as determined post-hoc) were assessed for
this potential. A potential to misclassify was only
present under two circumstances. First, if pathology
was normal in the left hemisphere but the PET image
was assessed as abnormal, this could be incorrectly
classified as a false positive if the pathologically unas-
sessed right hemisphere was the basis for calling the
image positive. However, there were no subjects with
this combination. Second, if pathology (based on the
left hemisphere) and PET assessments (based on both
hemispheres) were both negative but there was β-
amyloid pathology in the right hemisphere, then the
case might have been wrongly categorized as a true
negative when it would actually have been a false negative.
Of five cases meeting this criterion, 4 showed minimal
β-amyloid pathology; mCERADSOT values were 0, 0, 0
and 0.4, and all readers recorded negative PET assess-
ments for all regions. One subject (case 39) did have
left-sided cortical β-amyloid close to the threshold, but
again all readers uniformly recorded negative cortex
assessments from the bilateral [18F]flutemetamol image.
The literature also suggests that there is general bilat-
eral symmetry for β-amyloid by both PET [48] and
pathology [44].
Amyloid in neuritic plaques is the predominant β-amyloid
pathology imaged by PET
The assessment of neuritic plaques in neocortical re-
gions of the brains has been a key feature for the
diagnosis of AD and was expected to be the predom-
inant histopathological feature correlating with
[18F]flutemetamol PET image assessment. CERAD,
mCERADSOT, and mCERADmode neuritic plaque as-
sessments generally agreed, although the single-point es-
timate CERAD included disparities with mCERADSOT in
15/106 cases (14%) and was a less robust predictor of PET
image positivity than both mCERADSOT and mCERAD-
mode (Table 5). Four cases (4%) were dichotomised
Fig. 5 Cases in which there was disparity between the pathology dichotomy as normal or abnormal and PET negative or positive were associated
with low reader confidence (Panel a) and inter-reader agreement (Panel b). False-negative cases (FN) where the majority interpreted the PET image as
negative in the presence of an abnormal neuritic plaque burden were associated with low inter-reader agreement (P < 0.0001, Kruskal Wallis test).
False-positive (FP) cases were associated with low reader confidence (P < 0.0001, Kruskal Wallis test). Inter-reader agreement was determined as Fleiss’
kappa coefficient Pi (see text for details) which for 5 readers is 1 when all 5 readers are in agreement, 0.6 when the agreement is 4:1 and 0.4 when the
agreement is split 3:2. Reader confidence was recorded as a 5-point scale (1-5) with 5 being most certain and 1 being the least certain. Panel c In the 3
false-positive cases, although neuritic plaque frequency was below threshold, β-amyloid in the form of diffuse plaques was comparable to mCERADSOT
cases (true positives; TP). One case also had high % area stained for β-amyloid by IHC but was low intensity and the readers called this case true nega-
tive (TN) (reader ratio 5:0, Case 13) suggesting that in this case cortical β-amyloid levels in the absence of any neuritic plaques were insufficient to pro-
duce a positive image by PET. Another case had sufficient neuritic plaques (mCERADSOT 2.7) even though the % area stained was relatively low. For all
panels, boxes represent mean +/- 1 standard error and whiskers represent 95% confidence interval. Open circles represent outlier values and asterisks
represent extreme values (see Materials and methods for details)
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differently when using mCERADSOT vs. mCERADmode.
Significant plaque burdens in non-CERAD regions led to
the differential classification of only two cases (cases 26
and 74), supporting the general view that β-amyloid path-
ology limited to non-CERAD regions (anterior cingulate
and primary visual cortex in these cases) is atypical (2/
106 = 2%), but should not be ignored when comparing to
global cortical assessments used in β-amyloid PET im-
aging. Two further cases were dichotomised differently
due to the statistical method used (mean vs. mode) in sub-
jects with borderline β-amyloid pathology (cases 32 and
44). Indeed, discrepancies were only noted between any of
the three neuritic plaque assessment methods when the
burden was close to the threshold between sparse and
moderate. Since these differences were so few in number
and changed from false classifications (false negative, FN;
false positive, FP) to true classifications (true negative, TN;
true positive, TP) (and vice versa; case 26 FP→TN, case
32 TN→ FN, case 44 FP→TP, and case 74 FN→TN;
mCERADSOT→mCERADmode respectively), sensitivity
and specificity of majority PET reads were comparable for
the 2 methods (respectively 91% and 90% for mCERAD-
SOT and 92% and 87.5% for mCERADmode). These per-
formance measures were superior to those using the
single-point estimate CERAD assessment (91% and 76%
for sensitivity and specificity, respectively).
Comparison of CERAD single-point estimates and
mCERADSOT showed 15 disparate global assessments,
all of which were in the sparse or moderate categories
and close to the threshold between normal and abnor-
mal. This supports the superiority of repeated measures
over a single (or even duplicate) measure, but also high-
lights the potential for misclassification in any biological
continuum when close to a fixed threshold. The fact that
our SOT methods and the CERAD single point esti-
mates all correlate well with PET tracer retention di-
chotomy strongly supports the notion that neuritic
plaque burden is strongly associated with PET β-
amyloid imaging. The probability of a subject having a
positive PET image interpretation increased with neur-
itic plaque burden (Fig. 2a). Subjects with a sparse neur-
itic plaque frequency were equally as likely to have a
positive or negative PET image, suggesting that the
actual threshold of plaque burden that can be detected
by [18F]flutemetamol (between sparse and moderate) is
below the one generally accepted to be diagnostically
relevant for AD diagnosis (moderate or frequent) [41].
Both cortical neuritic (Bielschowsky) and total (β-amyl-
oid IHC) plaque burden was higher in the neocortex
with advancing disease progression as determined by the
β-amyloid phase [58] (Fig. 6) when measured as a single
CERAD categorical point estimate or by mCERADSOT
(Bielschowsky for neuritic plaques) or CERAD-like
categorical score (β-amyloid IHC for diffuse plaques).
This increase in cortical plaque burden was associated
with an increase in the probability of positive PET as-
sessment starting in phase 3 with near certainty in phase
5. The implication is that although neocortical plaques
are present in phases 1 and 2, these are below the limit
of detection by blinded visual assessment of [18F]flute-
metamol PET images and that the threshold of a nega-
tive or positive PET image is reached between phase 3
and phase 4. These data also illustrate the increasing
cortical β-amyloid burden associated with increasing
subcortical β-amyloid distribution.
The maximal regional mCERADSOT score was observed
most frequently in the middle temporal lobe in nearly half
of all abnormal cases (Table 6). Other CERAD regions
were also frequently observed to be the region of maximal
involvement. While the precuneus was assessed as positive
by PET in all BIE-abnormal cases, this region was only
classified as abnormal by pathology in 75% of the cases
globally classified as abnormal. Pathology in other regions
was variable. β-amyloid burden in the primary visual cor-
tex was highly variable. The maximal involvement of the
CERAD regions is in broad agreement with accumulated
histopathological studies that indicate a progressive spread
of β-amyloid deposition within the brain, beginning in the
Table 5 Summary statistics and case status for each of the β-amyloid dichotomy algorithms
Case status (5 readers per case) Pathology
Reference standard TN FP FN TP Normal Abnormal Sensitivitya Specificityb
mCERADSOT
c 131 19 33 347 30 76 91% 87%
mCERADmode
d 134 26 30 340 32 74 92% 84%
CERADe 134 51 30 315 37 69 91% 72%
Amyloid phasef 108 2 56 364 22 84 87% 98%
TN true negative, FP false positive, FN false negative, TP true positive
asensitivity (true positive rate) = TP/(TP + FN)
bspecificity (true negative rate) = TN/(TN + FP)
cAbnormal defined as any regional mCERADSOT score > 1.5). Note while these analyses are presented by individual reads, the a priori analysis was by majority read
(sensitivity was 91% and specificity was 90% by majority read N = 106)
dAbnormal defined as any CERAD region moderate or frequent (multiple measures)
eAbnormal defined as and CERAD region moderate or frequent (single point estimate)
fAbnormal defined as phase 3, 4 or 5
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lateral neocortex and basal neocortex [7] and spreading
through medial neocortex, subcortical diencephalon,
midbrain and then into the cerebellar and hindbrain struc-
tures [58]. These studies have also suggested that most
neocortical regions have a heavy burden by the time the
disease has progressed to symptomatic phases. While the
frequencies of β-amyloid abnormality (mCERADSOT > 1.5)
were greatest in CERAD regions (Table 6), there was no
significant difference in mean mCERADSOT between the
regions (P = 0.68; Kruskal-Wallis test N = 848). Of the 76
abnormal cases by mCERADSOT, 40 (53%) were abnormal
in all eight cortical regions and 70 (92%) were abnormal in
multiple regions. Only 6 cases (8%) were dichotomised as
abnormal on the basis of a single region and were
therefore theoretically more prone to misclassification. In-
deed, 3/6 of these single region dichotomies were discord-
ant with PET (i.e. false-negative PET assessment by
majority).
Analysis of the various histopathological scores
against PET assessment showed superiority of plaque
based assessments over neuropathological diagnoses.
ROC analysis was performed for BIE dichotomy
against categorical scores for CERAD (none, sparse,
moderate, frequent), NIA-RI AD likelihood (not, low,
intermediate high), NIA-AA AD neuropathologic
changes (none, low, intermediate, high) and amyloid
phase (phase 0–5) and for dichotomised neuropathol-
ogy (moderate or frequent CERAD, intermediate or
Table 6 Frequency of regional β-amyloid abnormality
Neocortical region
CERAD regions
MFL STG MTG IPL ACG PCG PRC PVC
Pathology
Frequency region maximala 13 (17%) 5 (7%) 33 (43%) 19 (25%) 8 (11%) 6 (8%) 12 (16%) 17 (22%)
Frequency region abnormal mCERADSOT >1.5
(of 76 abnormal cases)
61 (80%) 57 (75%) 65 (85%) 66 (87%) 56 (74%) 63 (83%) 57 (75%) 60 (79%)
PETb Frontalc Temporal Parietal PCG/PRC
Frequency abnormal 5 reads per case
(of 71 abnormal cases by majority)
326 (92%) 299 (84%) 323 (91%) 331 (93%)
MFL midfrontal lobe, STG superior temporal gyrus, MTG middle temporal gyrus, IPL inferior parietal lobe, ACG anterior cingulate gyrus, PCG posterior cingulate
gyrus, PRC Precuneus, PVC primary visual cortex
amultiple regions may be simultaneously the region of maximal involvement
bBIE assessment also included the subcortical striatal region which was abnormal in 302 assessments (85%)
cThe frontal lobe was also assessed with the anterior-most aspect of the anterior cingulate in BIE assessment
Fig. 6 Neocortical diffuse and neuritic plaque frequency and probability of PET positive interpretation increases with β-amyloid phase. Amyloid phase
represents a progression of plaque deposition with advancing AD starting in the neocortex (phase 0-2) and progressing into the midbrain (phase 3) and
hindbrain (phase 5). By phase 4, neocortical neuritic plaques are sufficiently abundant to be detectable by PET imaging. Panel a. The abundance of both
diffuse and neuritic plaques increase with advancing amyloid phase. The plots represent mean neocortical plaque frequencies (0 = none, 1 = sparse, 2 =
moderate and 3 = frequent) per amyloid phase and plaque frequency is determined by the CERAD single point estimate for each subject (N = 106). Panel
b. Neocortical plaque frequencies as determined by mCERADSOT using multiple measures per region (N= 106). Note three outliers (solid black circles) in
phase 4/5 with mCERADSOT below 1.5 meaning that these cases were considered normal by mCERADSOT but abnormal by amyloid phase. Two of these
cases (A and C) were false positives by majority, while B was true negative by majority, but only by a 3:2 reader split. Panel c. The probability of positive
global PET assessment increases with amyloid phase (N= 5 for each subject, N= 35, 50, 25, 70, 120 and 230 for phases 0–5 respectively). For all panels,
boxes represent mean +/- 1 standard error and whiskers represent 95% confidence interval. Open circles represent outlier values and asterisks represent
extreme values (see Materials and methods for details)
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high NIA-RI and NIA-AA, and phase 3 or more Thal
amyloid phase) against composite cortical SUVRs. In
both sets of analyses Thal amyloid phase gave the greatest
areas under the curve (>0.95) and this was slightly super-
ior to the ROC analysis of dichotomised BIE against the
continuous variable mCERADSOT of 0.949. (see Add-
itional files 2, 3, 4, 5 and 6).
The lower limit of β-amyloid detection by PET is of
diagnostic relevance
Three observations indicate that the lower limit of de-
tection of plaques by PET is just below the threshold of
plaque burden used for the diagnosis of AD, i.e. the
lower limit for the detection of plaques by [18F]fluteme-
tamol appears to be between the CERAD categories of
sparse and moderate (5-6 neuritic plaques per 100x
FoV). Firstly, the probability of an abnormal scan inter-
pretation is almost 0 for the CERAD category of none,
and almost 1 for the categories of moderate and
frequent, while it is approximately 0.5 for the sparse cat-
egory (Fig. 2a). Secondly, analysis of regional mCERAD-
SOT values shows that the probability of a region being
assessed as abnormal by PET increases between sparse
and the mid-point between sparse (mCERADSoT =1.0)
and moderate (mCERADSoT = 2.0), i.e. at mCERADSoT =
1.5. Above a score of 1.5, the probability plateaus
(Fig. 2b). Thirdly, ROC analysis of mapped regional his-
tometric endpoints (neuritic plaque density, β-amyloid
IHC area) and SUVR measures in all 8 neocortical re-
gions for a subset of 32 cases provided optimal sensitiv-
ity and specificity in the mCERADSOT range of 0.9 – 1.1,
corresponding to approximately 2-3 neuritic plaques per
100x FoV, in the middle of the sparse CERAD category
(Additional file 2) and representing β-amyloid levels that
are on average lower than those associated with clinico-
pathologically significant AD (cognitive impairment or
dementia due to AD).
β-amyloid is the primary amyloid target of
[18F]flutemetamol
Although amyloid in neuritic plaque burden probably
accounts for the majority of tracer retention, amyloid (β-
pleated sheet) structure is found in several protein ag-
gregates within the brain in AD and other neuropatho-
logical degenerative processes. The binding mechanism
of Thioflavin-T derivatives (such as flutemetamol) to β-
sheets in β-amyloid fibrils is not specific to the primary
peptide sequence [6, 41]. These alternative amyloid
deposits include other insoluble forms of β-amyloid
(diffuse plaques and CAA), as well as other forms of
amyloid, such as tau (neurofibrillary tangles [NFT]) and
α-synuclein (Lewy bodies). Our subject group contained
2 cases of tangle-predominant dementia and 1 case of
Pick’s disease, with minimal co-incidental β-amyloid
involvement. All 3 cases were PET negative, suggesting
that any cross reactivity to tau at these levels is insuffi-
cient to cause ambiguity to interpretation of β-amyloid-
based tracer retention. Despite β-amyloid deposits being
a commonly observed co-pathology in LBD subjects,
only 55% (16/29 cases) were diagnosed with co-incident
AD against the NIA-RI criteria, despite 79% (23/29)
being PET positive. Most LBD cases without β-amyloid
pathology were PET negative and therefore α-synuclein
deposits per se may not have a strong contribution to β-
amyloid PET imaging, as suggested by previous studies
[9, 19, 70]. Of the 13 LBD cases that were not coincident
with AD, 7 were mCERADSOT normal (4 PET negative
and 3 PET positive) and 6 were mCERADSOT abnormal
(5/6 PET positive). The 3 PET positive mCERADSOT
normal cases in this disease category represent the only
false positive cases in the GE067-026 trial and were
scrutinised in greater detail. Two of the three cases
(cases 29 and 44) were close to the >1.5 a priori thresh-
old for mCERADSOT. As the limit of detection is likely
below this threshold (see above), are probably only false
positive by virtue of this a priori threshold. However, the
third case (case 43) had very few neuritic plaques and
these were confined to the primary visual cortex, a region
not directly assessed in the PET BIE. Two of these 3 cases
had not had β-amyloid IHC % area measurements, and so
were added to the original 30 cases in a post hoc analysis.
Both were determined to have a high percentage of tissue
area occupied by β-amyloid (Table 1).
Only 3 cases of CAA were recorded in the absence of
a diagnosis of AD, and 2 of these were determined to be
mCERADSOT normal. Both were PET negative. For one
case CAA involvement was focal and minimal, whereas
the other was more extensive, i.e. Vonsattel grade 2,
stage 2, and type 1 [56, 64]. With so few cases of CAA
in the absence of AD (or accompanying plaque burden),
no firm inference can be made regarding the contribu-
tion of CAA to tracer retention. Furthermore, composite
SUVRcer of AD subjects with and without CAA were
comparable (P > 0.5, ANOVA). However, indirect evi-
dence that CAA might add to cortical tracer retention
may be seen in cases where cortical β-amyloid in the
form of neuritic plaques is already close to but below
the threshold of detection, i.e. in the 14 amyloid phase 3
cases. In this small subset, CAA was recorded in all 8
cases in which the majority BIE assessment was abnor-
mal and was absent in 5/6 cases where the BIE assess-
ment was normal. The remaining case with majority
normal BIE had only focal CAA. The mCERADSOT
scores for these 14 cases were comparable, while the
probability of a BIE assessment as abnormal and the
cortical composite SUVRs were increased (Fig. 7).
Although the contribution of diffuse plaques to tracer
retention is difficult to determine precisely, 2
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observations suggest that there is significant binding to
diffuse plaques in this study. Firstly, the unequivocally
positive PET assessment of case 43 in the virtual absence
of neuritic plaques or CAA is possibly explained by the
significant cortical diffuse plaque burden, 9.4% of the
grey matter stained with β-amyloid IHC (Fig. 6, Panel c).
Furthermore, any plaque burden in the striatum is pre-
dominantly in the form of diffuse plaques [20] and this
region was frequently determined to be PET abnormal
in our cohort. The term diffuse plaque covers a range of
lesions from fleecy amorphous β-amyloid deposits
through to plaques that are morphologically better
defined but lack the dense core or dystrophic neurites
required to be identified as neuritic. Although it has be-
come commonly assumed that diffuse plaques do not
contain fibrillar amyloid, electron microscopic observa-
tions have indicated that diffuse plaques contain sparse,
loosely-textured amyloid fibrils [69] and many diffuse
plaques fluoresce weakly with thioflavin S [15] indicating
that fibrillar amyloid is often present, although at lower
densities than within neuritic or core-only plaques. Also,
while the concentration of fibrillar β-amyloid may be
substantially lower within diffuse, as opposed to neur-
itic plaques, the volume occupied by diffuse plaques
can be many times greater [43]. These observations
support that, while being uncommon occurrence, a
Fig. 7 CAA contributes weakly to PET cortical positivity. In amyloid phase 3 cases, where cortical neuritic plaque load is borderline (Panel a), PET
assessment as abnormal is more likely (P = 0.0001, Kuskal Wallis test) in the presence of CAA (Panel b) and SUVR is elevated (Panel c, P < 0.05
Spearman). Panel d. Probability of positive BIE assessment for all subjects demonstrating that this analysis is only possible in cases with a modest
plaque burden (Moderate or phase 3 cases) because of a lack of amyloid angiopathy in phase 0–2 and certain cortical positivity due to abundant
cortical neuritic plaques in Phase 4 and 5. Panel e. A similar pattern if observed with regional analysis (frontal, temporal, parietal and striatum). It is
likely that this effect is subtle and additive to a neocortical plaque burden already close to the threshold. Boxes represent mean +/- 1 standard
error and whiskers represent 95% confidence interval. Open circles represent outlier values and asterisks represent extreme values (see Materials
and methods for details)
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heavy diffuse plaque burden in the absence of neuritic
plaques may be sufficient to generate an abnormal
tracer retention signal.
Where pathology and PET imaging disagree
In our cohort of 106 subjects, the majority BIE read was
disparate from the neuritic plaque assessment in 10
cases, 3 of which were false positives (abnormal PET
image with normal pathology) and 7 of which were false
negatives (normal PET images with abnormal path-
ology). Of these 10 cases, half had neuritic plaque dens-
ity scores near the threshold (see below), but in the
other 5 cases (cases 27, 28, 41, 42 and 43) there was no
overt reason for the disparity, as the neuritic plaque
density score was not considered borderline. Only one
of the unexplained cases (case 43) was a false positive
without a significant neuritic plaque burden (mCERAD-
SOT = 0.3, see earlier comments on heavy diffuse plaque
burden in this case). A CERAD assessment of moderate
entered onto the case report form was not substantiated
by the mCERADSOT score nor the neuropathology
report, and was deemed a transcription error from
“moderate diffuse plaque frequency,” which was re-
corded in the report. However, whilst there is little doubt
that the cortical plaque burden was low, the % grey-
matter area stained with β-amyloid IHC was high (see
Fig. 3), the amyloid phase was 4, the Braak stage was III,
and the patient had a history of dementia. Because of
the scarcity of neuritic plaques and presence of signifi-
cant Lewy bodies, the primary diagnosis for this case
was LBD. Interestingly, this case would be considered as
having intermediate AD neuropathology changes if using
the more recent National Institute on Aging-Alzheimer's
Association (NIA-AA) diagnostic criteria [25].
The remaining 4 cases were false negatives with un-
equivocally abnormal β-amyloid burdens. The mCER-
ADSOT scores for these cases were 1.8, 2.1, 1.9, and 2.7
for cases 27, 28, 41, and 42, respectively (Table 1). It is
possible that the increased partial volume effect pro-
duced by severe neocortical atrophy may be at least
partially responsible for the misclassification, although
equivalent atrophy was seen in many patients whose im-
ages were correctly interpreted. Three of these 4 cases had
a modest neuritic plaque burden and only one of them
had a heavy neuritic plaque burden (mCERADSOT = 2.7,
case 42). This last case should not have escaped PET de-
tection. Indeed, in this case (case 42), 2/5 readers recorded
abnormal retention in 4 of the 5 regions assessed, and
all 5 readers reported low confidence in interpreting
this image.
Most disparities occurred in cases with sparse or
moderate neuritic plaque densities. The differentiation
between sparse (1 to 5 plaques) and moderate (6 to 19
plaques) may differ by one plaque per field of view, and
some misclassification is therefore inevitable when the
underlying pathology is close to a threshold. Indeed, half
of the disparity cases had β-amyloid pathology categories
straddling the threshold for dichotomy (sparse and
moderate) and amyloid phase 3 (4/10). Of the 7 false
negative cases, only 1/7 (14%) was abnormal for all 8
cortical regions assessed compared to 39/69 (56%) in
true positive cases. The remaining cases varied from 1 to
5 regions abnormal (out of the 8 sampled). Furthermore,
of 6 cases classified as abnormal on the basis of abnormal
pathology in a single region, half were classified as false
negatives. However, it is important to determine whether
additional factors could contribute to misclassification.
In a post-hoc analysis, we classified cases as equivocal
by either PET or pathology against the following defined
criteria; equivocal by pathology if the mCERADSOT max
was 1.25 – 1.75, based on a theoretical influence of 1
aberrant measure on a regional assessment; 5 slides
scored as 1.5 and one slide scored as 0 (mCERADSOT =
1.25) or 3 (mCERADSOT = 1.75); equivocal by PET if
fewer than 4/5 readers concurred; i.e., if majority assess-
ment was 3:2, or if reader confidence was low (mean
confidence of less than 4 on a scale of 1–5). A total of
24 cases were equivocal by either PET or pathology
criteria; 6 cases were equivocal by both criteria. Fourteen
cases were considered as equivocal by pathology, 12 with
borderline mCERADSOT and 6 with mCERADSOT > 1.5
based on a single region (4 cases met both criteria).
Sixteen cases were equivocal by PET, all with low reader
confidence and 4 of these also by split majority (3:2
reader ratio). Interestingly, of these 16 cases, half were
amyloid phase 3, or the preclinical to clinical transition
phase (P < 0.01, χ2 test; observed vs. expected), indicating
that at this intermediate level of AD β-amyloid path-
ology, the images are less easy to interpret. Indeed, of
the 14 phase 3 cases, only half were interpreted as posi-
tive by BIE majority. Of the 10 cases that were false posi-
tive or false negative by PET majority read, half were
equivocal by pathology.
Discussion
The data presented in this study examined the histo-
pathology underlying [18F]flutemetamol tracer retention
and PET image interpretation. The cohort of 106 end-
of-life subjects represented a broad and continuous
spectrum of β-amyloid pathology and other comorbidi-
ties, including several cases where the neuritic plaque
burden was diagnostically equivocal. Such cases are valu-
able for a critical assessment of imaging agent perform-
ance and diagnostic limitations.
No subjects were designated as abnormal by majority
PET interpretation in the absence of fibrillar β-amyloid
plaques. This study, and others using alternative β-
amyloid PET tracers, demonstrate that neocortical
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neuritic plaque burden is the most important β-amyloid
histopathological feature underlying tracer retention
[11]. Key to demonstrating this was the reliable assess-
ment of the neuritic plaque burden through multiple
regional assessments that considerably improved upon a
single point CERAD assessment, which is vulnerable to
sampling bias and inter-reader variability [1]. Additionally,
rather than limiting histopathological or PET analysis to
the 3 anatomic regions originally recommended by
CERAD, global cerebral tracer retention, which is reflect-
ive of global cerebral β-amyloid deposition, is validated by
the good efficacy of multiple trials and tracers [11, 12, 28,
31, 35–38, 47, 50–52, 65–67]. Indeed, interpretation of
PET images may be enhanced by the inclusion of medial
cerebral gyri, notably the cingulate and precuneus, regions
that have not previously formed part of the standard
neuropathology assessment. In practice, assessment as ab-
normal based upon a single region is unusual. Only a sin-
gle case (<1%) in our cohort was designated as abnormal
based upon a single positive PET region. Interestingly this
case has borderline amyloid burden (case 49). Although
tissue sections are relatively thin, in coronal cross section
they cover a cortical area (3–5 cm) comparable to that
assessed by PET and are unlikely to be a cause of discrep-
ancy between the pathology and PET, especially if 8 (or
more) cortical regions are assessed and multiple plaque
measures per section also mitigated plaque heterogeneity.
Furthermore, there is likely to be merit in assessment of
subcortical areas such as the striatum [5] which is signifi-
cant in amyloid progression [25, 57].
Unsurprisingly, the single most confounding factor in
image interpretation is equivocal pathology, where the
underlying histopathology is near the limit of reliable
detection in PET images. In the present multi-reader
study, this was manifest in low reader confidence and
disagreement between the multiple readers. In clinical
practice, it will probably be beneficial to consider a cat-
egorical assessment of “equivocal”, an option which was
not made available to readers during efficacy trials due
to the regulatory requirement of dichotomy. Import-
antly, the detectable neuritic plaque burden by [18F]flu-
temetamol imaging is diagnostically relevant in that it
aligns with what is the accepted distinction between nor-
mal and pathologic levels of β-amyloid burden used for
AD diagnosis. However, the probability of a positive PET
assessment is non-zero in the sparse CERAD category
and over a range of mCERADSOT scores between 1 and
2 (sparse to moderate). It is possible that varying PET
methodology may be able to alter the threshold for call-
ing a scan positive. Paradoxically, better PET sensitivity
will cause worse accuracy for predicting cognitive im-
pairment due to AD as too many sparse-plaque cases
will be called PET positive. On the other hand, detecting
more of the sparse plaque cases may be better for
subject selection for prevention trials for AD, as the
chance of success for such trials will presumably be bet-
ter for those subjects at an earlier disease stage. The
lower limit of detection of plaques by amyloid tracers may
vary by anatomical region and partial volume effects, but
it appears likely from these results that flutemetamol may
detect cortical plaques below the threshold normally asso-
ciated with a clinically significant “moderate” plaque
burden and further quantitative methodological studies
are needed.
Mixed pathologies in this cohort enabled us to investi-
gate how co-incident pathology may impact PET image
interpretation. Amyloidopathies other than those contain-
ing β-amyloid (i.e. tauopathies and synucleinopathies) did
not clearly interfere with β-amyloid PET interpretation,
most likely through a lack of detectable signal. We cannot
comment on the potential for a weak signal in areas not
assessed in this study, e.g. mesial temporal for Tau). How-
ever, other forms of β-amyloid deposits such as diffuse
plaques and CAA possibly contribute to overall tracer
retention. These forms of β-amyloid are often associated
with AD, but are also seen as separate entities, in that they
are occasionally recorded in the absence of typical AD
neuritic plaque and NFT neuropathology. The β-amyloid
burden in the form of diffuse plaques is variable, as the
term covers a range of lesions with varying β-amyloid
density and fibrillar β-amyloid content. Nonetheless, fre-
quent diffuse plaques alone were sufficient for PET posi-
tivity in the cortex of one case (case 43) and in the
striatum in 9 cases - in agreement with in vitro studies of
flutemetamol and the chemically related PiB, which lightly
stain diffuse plaques [28].
While at first impression, the inability to discriminate
between a significant diffuse plaque burden and a more
modest neuritic plaque burden may appear to be a
disadvantage, this may not be a critical weakness, as
cases with a heavy load of cortical diffuse plaques but
absent or scarce neuritic plaques are uncommon. Also,
more importantly, such cases may meet current diagnos-
tic criteria for clinicopathologically significant AD as
exemplified by case 43, which met the 2012 AD criteria
[25]. Indeed, such tracer retention by diffuse plaques
may be a diagnostic advantage in regions such as the
striatum, where plaques are predominantly diffuse [16]
yet are diagnostically indicative of an advanced β-
amyloid phase [58], and may also be used to predict
associated NFT stage [16]. In this latter study, striatal β-
amyloid identified AD pathology in the presence of Lewy
body disease, which is analogous to some of our sub-
jects. Striatal β-amyloid detection may be particularly
important in some cases of presenilin-1 (PS1)-associated
AD where the striatum may be the first area affected
[34]. However, to our knowledge, we did not have any
PS1 mutations in this study. The presence of plaques in
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the striatum represents a transition from amyloid phase
2 (Normal) to phase 3 (Abnormal) [58]. However, in the
early stages of phase 3 amyloid burden is likely to be in-
sufficient to be detected by PET imaging and the burden
in the striatum may not become sufficient until phase 4.
Indeed, in the 6 cases where PET assessment was posi-
tive in the cortex but negative in the striatum 4 were
classified as phase 3 and 2 were classified as phase 4.
We are currently assessing the significance of striatal
imaging in further depth (see also changes to the AD
diagnostic criteria below).
While the β-amyloid in cortical diffuse plaques may not
often be clinically significant on its own, the deposits of β-
amyloid in CAA confer a substantial risk of lobar haemor-
rhage. Therefore, the ability of β-amyloid tracers to iden-
tify CAA is of considerable interest [3, 30]. While others
have reported positive PET signal with CAA using the
chemically related [11C]PiB [3, 30], our cohort contained
no cases with CAA in the absence of at least some fibrillar
β-amyloid plaques. Nonetheless, CAA may contribute to
cerebral PET positivity in a subset of cases supporting
reports that CAA is detectable by others [2] but that,
although substantial amounts of β-amyloid may be
present in vasculature, tracer retention by CAA is modest
compared to that by cortical neuritic plaques. Our analysis
did not include PET image assessment of the occipital
lobe, where others report predominant CAA tracer reten-
tion [2]. Any potential clinical utility of β-amyloid tracers
with regards to CAA may rest mainly in the ability to rule
out CAA with a negative scan, in much the same way as a
negative scan also rules out AD.
Significant cortical atrophy in end-stage Alzheimer’s dis-
ease can complicate the interpretation of [18F]flutemetamol
PET images, which requires assessment of pathological
gray-matter retention adjacent to normal white-matter re-
tention pattern. In most circumstances, this is relatively
straightforward, but may be complicated by significant atro-
phy of the cortical ribbon, rendering differentiation be-
tween grey and white matter more difficult in the PET only
image. As atrophy is a common feature of advanced AD, at-
rophy in the cohort as a whole was generally more frequent
with increased positive PET images, reflecting the under-
lying advanced AD. However, in cases where atrophy was
recorded as severe, the probability of a positive PET inter-
pretation decreased without a concurrent drop in reader
confidence. Four of the seven false negative cases were
noted to have severe atrophy during gross examination at
post-mortem. It therefore appears likely that while equivo-
cal pathology is associated with low reader confidence -
and likely accounts for some of the false negative cases - at-
rophy probably accounts for some of the false-negative in-
terpretations without a concurrent drop in reader
confidence. While amyloid pathology is generally symmet-
ric in distribution, focal atrophy present in some of our
cases showed distinct laterality, resulting in an asymmetric
PET image. The electronic training program for image in-
terpretation [54, 63] provides guidance on how to interpret
images with such focal atrophy.
Our results demonstrate an association of [18F]flute-
metamol PET with β-amyloid deposition in the neocor-
tex, while PET positivity correlated less well with a
neuropathologically-supported diagnosis of AD. The AD
diagnostic criteria used here were the National Institute
of Aging – Reagan Institute criteria [26]. The association
between neuritic β-amyloid plaques and NFT is imper-
fect [21], and so any measure of β-amyloid in the cortex
cannot ‘rule in’ AD, as it is unable to measure NFT. In-
stead, its utility is primarily intended to ‘rule out’ AD if
the PET scan is negative. However, the PET detection of
striatal plaque burden may offer a more sensitive assess-
ment of AD progression [16] and a recent revision of
AD diagnostic guidelines [25], which includes β-amyloid
phase analysis [58], indicates that striatal imaging may
refine AD assessment with β-amyloid tracers.
The GE067-026 trial findings presented here for
[18F]flutemetamol are consistent with those reported pre-
viously in cerebral biopsy trials and by other β-amyloid
imaging agents in end-of-life subjects, such as the
chemically related [11C]PiB and chemically less similar
[18F]AV-45, supporting the utility of β-amyloid imaging in
vivo [11, 28, 67]. The ‘holy grail’ for subject selection for
prevention trials would be detection of early or preclinical
plaque burden with a detection limit clearly below the
levels that are associated with significant cognitive decline.
The probability of a positive PET image interpretation in
this study was 50% in the sparse category, suggesting that
this may be possible, but it seems likely that analysis of
other regions, such as the striatum or, better yet, a meas-
urable, reliable quantification method, would likely im-
prove the lower detection limit, enabling assessment of β-
amyloid in preclinical AD, a stage of disease almost cer-
tainly more amenable to preventative treatment strategies
or disease-modifying therapeutics. In this context, it is ne-
cessary to note that recent studies reported that amyloid
PET only detects cases with already advanced amyloid
phases (3 and higher) whereas initial phases (1 and 2)
could not be identified with [18F]flutemetamol or [11C]PIB
[45, 55]. Conversely, increasing the sensitivity of PET β-
amyloid scans may decrease the specificity to predict clin-
ically significant AD neuropathology. It is possible that
PET image interpretation methods might be adjustable to
fit the clinical setting, with a less sensitive scan (similar to
those currently in use) being used in the setting of demen-
tia and a more sensitive scan used in the setting of selec-
tion of cognitively normal, β-amyloid positive subjects for
AD prevention trials.
β-amyloid PET imaging studies with neuropathology val-
idation in post-mortem brains [2, 9–11, 27, 28, 32, 33, 45,
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53, 62] or biopsy brain tissues [37, 50, 51, 67] are usually
limited by small numbers of subjects and could be biased
by variable time between PET acquisition and autopsy or
biopsy. However, our study of 106 subjects is a relatively
large cohort and the influence of variable PET to autopsy
interval was not a significant factor [49]. Small numbers of
disease transition subsets, such as 14 amyloid phase 3 sub-
jects, show interesting results – low reader confidence, low
inter-reader agreement and possible influence of CAA –
and while analyses reach statistical significance, conclu-
sions drawn from small numbers such as these require fur-
ther research to substantiate or refute these findings.
Conclusions
In summary, examination of data from an end-of-life clinical
trial of Flutemetamol F 18 Injection demonstrated a high
specificity and sensitivity for β-amyloid pathology, and de-
tection of a diagnostically relevant neuritic plaque burden.
Abnormal PET scans were always associated with under-
lying AD histopathology and equivocal PET scan reads usu-
ally indicated some underlying AD histopathology, possibly
at levels usually associated with cognitive normality or early
mild cognitive impairment. Other co-morbidities did not
interfere with image interpretation, although advanced cor-
tical atrophy could hamper interpretation even in advanced
AD cases. For the future, opportunities to quantify or auto-
mate the interpretation of PET images [59] and the study of
greater numbers of subjects in the intended target popula-
tion may further refine the clinical utility of β-amyloid PET
imaging following Flutemetamol F 18 Injection.
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Additional file 1: Example of the recording of pathology sampling to
enable mapped cortical tracer retention SUVRs to be measured for
correlation. Regions sampled from the lateral surface include the
Midfrontal lobe (MFL), Superior Temporal Gyrus (STG), Middle Temporal
Gyrus (MTG) and Inferior Parietal Lobe. Regions sampled from the medial
surface include Anterior Cingulate Gyrus (ACG), Posterior Cingulate Gyrus
(PCG), Precuneus (PRC) and Primary Visual Cortex (PVC). (DOC 90 kb)
Additional file 2: Receiver operator characteristic (ROC) analysis of
regional histometric measures and standard retention value ratios.
Regional analysis of 32 brains provided retention correlation with plaque
burden and provided a large data set (N = 256) with which to estimate
the lower limit of detection. For regional analysis SUVR baselines which
varied between regions due to variable adjacent white-matter signal
bleed were used to define a threshold for each region. Thresholds were
determined post-hoc by ROC analysis as the maximal sum of the sensitiv-
ity (true positive rate) and specificity (1 - false-positive rate). (DOC 59 kb)
Additional file 3: ROC Analysis - Dichotomised BIE (majority read) vs
categorical neuropathology. Comparison of the 4 histopathological
criteria of assigning abnormal amyloid against a dichotomised
(Abnormal/Normal) majority blinded PET Image evaluation. The 4 criteria
shown are CERAD [43], National Institutes of Ageing – Reagan Institute
AD diagnosis [26], National Institutes of Ageing – Alzheimer’s Association AD
diagnosis [25] and Amyloid phase (Phase 3 or greater) [58]. (DOC 201 kb)
Additional file 4: ROC Analysis: Dichotomised pathology vs continuous
SUVR. Comparison of 5 histopathological criteria of assigning abnormal
amyloid against PET signal quantification (SUVR). Histopathological criteria
used were: CERAD [43] moderate or frequent = abnormal; National
Institutes of Ageing – Reagan Institute [26] Intermediate or High =
abnormal; National Institutes of Ageing – Alzheimer’s Association [25]
Intermediate or High = abnormal; Thal 3+ Thal amyloid phase [58] of 3
or higher = abnormal; Thal 4+ Thal amyloid phase [58] of 4 or 5 =
abnormal. (DOC 241 kb)
Additional file 5: Clinical Status of subjects at PET Scan. Spontaneously
recorded clinical notes captured at the time of PET scan. The PET
category provided reflects PET majority image assessment against
pathology dichotomy normal/abnormal by mCERADSOT. (DOC 155 kb)
Additional file 6: Amyloid plaque frequencies. In addition to the
neuritic plaque frequencies assessed on Bielschowsky silver stained
sections, semiquantitative plaque frequencies of none, sparse, moderate
or frequent [43] were obtained from β-amyloid stained sections. In
addition to the frequencies recorded in the CERAD neocortical regions,
the Amyloid phase was recorded after examining multiple cortical,
subcortical, midbrain and hindbrain regions [58]. (DOC 112 kb)
Acknowledgements
We wish to acknowledge Stacy Simpson Logan, CMPP, of Winfield
Consulting, for her editorial assistance, funded by GE Healthcare and Dr Jan
Wolber for critical manuscript review. This study was funded by GE
Healthcare.
Authors’ contributions
PS, CJB, KH, PAJ, MZ, GF, APLS designed the GE067-026 clinical trial. CJB and
KH were responsible for oversight of blinded Vizamyl PET assessments. APLS
was responsible for oversight of blinded pathology assessments. GF was
Vizamyl Project Director. MDI, CAM, WEK were consulted for clinical trial
design prior to initiation. AC, JI, AI, CS, DRT were subcontracted by Covance
Ltd for blinded neuropathological analyses. TGB was subcontracted by GE for
blinded post-hoc striatal neuropathology analysis. MDI & APLS prepared the
manuscript. MZ, APLS performed statistical analysis. All authors approved the
final manuscript.
Competing interest
The authors APLS, CB, KH, PS, PAJ, MZ and GF are full time employees of GE
Healthcare. MDI, AC, JI, AI, CS, TGB and DRT served as paid research consultants
to GE Healthcare. TGB is also a paid research consultant to Avid
Radiopharmaceuticals. CAM and WEK are the co-inventors of [18F] flutemetamol
and have a conflict of interest as the result of a license agreement between the
University of Pittsburgh and GE Healthcare for [18F] flutemetamol technology.
Author details
1Department of Neurology, University of Pittsburgh, Pittsburgh, PA 15213,
USA. 2GE Healthcare, The Grove Centre (GC18), White Lion Road, Amersham,
Buckinghamshire HP7 9LL, UK. 3GE Healthcare, 75184 Uppsala, Sweden.
4Department of Surgical Sciences, Uppsala University, 75185 Uppsala,
Sweden. 5GE Healthcare, Marlborough, MA 01752, USA. 6Department of
Radiology, University of Pittsburgh, Pittsburgh, PA 15213, USA. 7Department
of Psychiatry, University of Pittsburgh, Pittsburgh, PA 15213, USA. 8Pathology
and Tumour Biology, Leeds Institute of Molecular Medicine, St James’s
University Hospital, Leeds, UK. 9National CJD Research & Surveillance Unit
University of Edinburgh Western General Hospital Edinburgh, EH4 2XU
Edinburgh, UK. 10Academic Department of Neuropathology, Centre for
Clinical Brain Sciences, Edinburgh EH16 4SB, UK. 11Department of
Neuroscience - Laboratory for Neuropathology, KU-Leuven, Leuven, Belgium.
12Banner Sun Health Research Institute, Sun City, AZ 85351, USA. 13Geriatric
Research Education and Clinical Center, VA Pittsburgh Healthcare System,
Pittsburgh, USA. 14Department of Pathology, UZ Leuven, Leuven, Belgium.
Received: 16 November 2016 Accepted: 29 November 2016
References
1. Alafuzoff I, Pikkarainen M, Arzberger T, Thal DR, Al-Sarraj S, Bell J, Bodi I,
Budka H, Capetillo-Zarate E, Ferrer I, Gelpi E, Gentleman S, Giaccone G,
Kavantzas N, King A, Korkolopoulou P, Kovacs GG, Meyronet D, Monoranu C,
Parchi P, Patsouris E, Roggendorf W, Stadelmann C, Streichenberger N,
Ikonomovic et al. Acta Neuropathologica Communications  (2016) 4:130 Page 22 of 24
Tagliavini F, Kretzschmar H (2008) Inter-laboratory comparison of
neuropathological assessments of beta-amyloid protein: a study of the
BrainNet Europe consortium. Acta Neuropathol 115:533–546
2. Bacskai BJ, Frosch MP, Freeman SH, Raymond SB, Augustinack JC, Johnson
KA, Irizarry MC, Klunk WE, Mathis CA, DeKosky ST, Greenberg SM, Hyman BT,
Growdon JH (2007) Molecular imaging with Pittsburgh Compound B
confirmed at autopsy: a case report. Arch Neurol 64:431–434
3. Baron JC, Farid K, Dolan E, Turc G, Marrapu ST, O'Brien E, Aigbirhio FI, Fryer
TD, Menon DK, Warburton EA, Hong YT (2014) Diagnostic utility of amyloid
PET in cerebral amyloid angiopathy-related symptomatic intracerebral
hemorrhage. J Cereb Blood Flow Metab 34:753–758
4. Beach TG, Monsell SE, Phillips LE, Kukull W (2012) Accuracy of the clinical
diagnosis of Alzheimer disease at National Institute on Aging Alzheimer
Disease Centers, 2005-2010. J Neuropathol Exp Neurol 71:266–273
5. Beach TG, Thal DR, Zanette M, Smith A, Buckley C (2016) Detection of
striatal amyloid plaques with [18 F] flutemetamol: validation with
postmortem histopathology. J Alzheimers Dis 52:863–873
6. Biancalana M, Koide S (2010) Molecular mechanism of Thioflavin-T binding
to amyloid fibrils. Biochim Biophys Acta 1804:1405–1412
7. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related
changes. Acta Neuropathol 82:239–259
8. Braak H, Braak E (1997) Frequency of stages of Alzheimer-related lesions in
different age categories. Neurobiol Aging 18:351–357
9. Burack MA, Hartlein J, Flores HP, Taylor-Reinwald L, Perlmutter JS, Cairns NJ
(2010) In vivo amyloid imaging in autopsy-confirmed Parkinson disease
with dementia. Neurology 74:77–84
10. Cairns NJ, Ikonomovic MD, Benzinger T, Storandt M, Fagan AM, Shah AR,
Reinwald LT, Carter D, Felton A, Holtzman DM, Mintun MA, Klunk WE, Morris
JC (2009) Absence of Pittsburgh compound B detection of cerebral amyloid
beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of
Alzheimer disease: a case report. Arch Neurol 66:1557–1562
11. Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM,
Fleisher AS, Reiman EM, Sabbagh MN, Sadowsky CH, Schneider JA, Arora A,
Carpenter AP, Flitter ML, Joshi AD, Krautkramer MJ, Lu M, Mintun MA,
Skovronsky DM (2012) Cerebral PET with florbetapir compared with
neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a
prospective cohort study. Lancet Neurol 11:669–678
12. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA,
Pontecorvo MJ, Hefti F, Carpenter AP, Flitter ML, Krautkramer MJ, Kung HF,
Coleman RE, Doraiswamy PM, Fleisher AS, Sabbagh MN, Sadowsky CH,
Reiman EP, Zehntner SP, Skovronsky DM (2011) Use of florbetapir-PET for
imaging beta-amyloid pathology. JAMA 305:275–283
13. Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I,
Arnold SE, Attems J, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Gearing M,
Grinberg LT, Hof PR, Hyman BT, Jellinger K, Jicha GA, Kovacs GG, Knopman
DS, Kofler J, Kukull WA, Mackenzie IR, Masliah E, McKee A, Montine TJ,
Murray ME, Neltner JH, Santa-Maria I, Seeley WW, Serrano-Pozo A, Shelanski
ML, Stein T, Takao M, Thal DR, Toledo JB, Troncoso JC, Vonsattel JP, White
CL, Wisniewski T, Woltjer RL, Yamada M, Nelson PT (2014) Primary age-
related tauopathy (PART): a common pathology associated with human
aging. Acta Neuropathol (Berl) 128:755–766
14. Curtis C, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, Beach TG,
Duara R, Fleisher AS, Frey KA, Walker Z, Hunjan A, Holmes C, Escovar YM, Vera
CX, Agronin ME, Ross J, Bozoki A, Akinola M, Shi J, Vandenberghe R, Ikonomovic
MD, Sherwin PF, Grachev ID, Farrar G, Smith AP, Buckley CJ, McLain R, Salloway
S (2015) Phase 3 trial of flutemetamol labeled with radioactive fluorine 18
Imaging and neuritic plaque density. JAMA Neurol 72(3):287–294
15. Dickson DW, Wertkin A, Mattiace LA, Fier E, Kress Y, Davies P, Yen SH (1990)
Ubiquitin immunoelectron microscopy of dystrophic neurites in cerebellar
senile plaques of Alzheimer’s disease. Acta Neuropathol 79:486–493
16. Dugger BN, Serrano GE, Sue LI, Walker DG, Adler CH, Shill HA, Sabbagh MN,
Caviness JN, Hidalgo J, Saxon-Labelle M, Chiarolanza G, Mariner M, Henry-
Watson J, Beach TG (2012) Presence of striatal amyloid plaques in
parkinson’s disease dementia predicts concomitant Alzheimer’s disease:
usefulness for amyloid imaging. J Parkinsons Dis 2:57–65
17. Effectiveness of an Electronic Training Program for Orienting and
Interpreting [18 F] Flutemetamol Positron Emission Tomography (PET)
Images NCT01672827. Last Updated: 12-18-2013. https://clinicaltrials.gov/
ct2/show/NCT01672827?term=NCT01672827&rank=1 Accessed 7-20-2015.
18. Fleiss JL (1971) Measuring nominal scale agreement among many raters.
Psychol Bull 76:378–382
19. Fodero-Tavoletti MT, Smith DP, McLean CA, Adlard PA, Barnham KJ, Foster LE,
Leone L, Perez K, Cortes M, Culvenor JG, Li QX, Laughton KM, Rowe CC,
Masters CL, Cappai R, Villemagne VL (2007) In vitro characterization of
Pittsburgh compound-B binding to Lewy bodies. J Neurosci 27:10365–10371
20. Gearing M, Levey AI, Mirra SS (1997) Diffuse plaques in the striatum in
Alzheimer disease (AD): relationship to the striatal mosaic and selected
neuropeptide markers. J Neuropathol Exp Neurol 56:1363–1370
21. Geddes JW, Tekirian TL, Soultanian NS, Ashford JW, Davis DG, Markesbery
WR (1997) Comparison of neuropathologic criteria for the diagnosis of
Alzheimer's disease. Neurobiol Aging 18:S99–S105
22. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ,
Wood NW, Colosimo C, Dürr A, Fowler CJ, Kaufmann H, Klockgether T, Lees
A, Poewe W, Quinn N, Revesz T, Robertson D, Sandroni P, Seppi K, Vidailhet
M (2008) Second consensus statement on the diagnosis of multiple system
atrophy. Neurology 71(9):670–676
23. Hauw JJ, Daniel SE, Dickson D, Horoupian DS, Jellinger K, Lantos PL, McKee
A, Tabaton M, Litvan I (1994) Preliminary NINDS neuropathologic criteria for
Steele-Richardson-Olszewski Syndrome (progressive Supranuclear Palsy).
Neurology 44(11):2015–2019
24. Herholz K, Ebmeier K (2011) Clinical amyloid imaging in Alzheimer's disease.
Lancet Neurol 10:667–670
25. Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW,
Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR,
Thies B, Trojanowski JQ, Vinters HV, Montine TJ (2012) National Institute on
Aging-Alzheimer’s Association guidelines for the neuropathologic assessment
of Alzheimer's disease. Alzheimers Dement 8:1–13
26. Hyman BT, Trojanowski JQ (1997) Consensus recommendations for the
postmortem diagnosis of Alzheimer disease from the National Institute on
Aging and the Reagan Institute Working Group on diagnostic criteria for
the neuropathological assessment of Alzheimer disease. J Neuropathol Exp
Neurol 56:1095–1097
27. Ikonomovic MD, Abrahamson EE, Price JC, Hamilton RL, Mathis CA, Paljug WR,
Debnath ML, Cohen AD, Mizukami K, DeKosky ST, Lopez OL, Klunk WE (2012)
Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging,
biochemical, and immunohistochemical study. Acta Neuropathol 123:433–447
28. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas
ND, Lopresti BJ, Ziolko S, Bi W, Paljug WR, Debnath ML, Hope CE, Isanski BA,
Hamilton RL, DeKosky ST (2008) Post-mortem correlates of in vivo PiB-PET
amyloid imaging in a typical case of Alzheimer's disease. Brain
131:1630–1645
29. Jellinger KA, Attems J (2007) Neurofibrillary Tangle-Predominant Dementia:
Comparison with Classical Alzheimer Disease. Acta Neuropathol 113(2):107–117
30. Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, Moran EK, Smith
EE, Rosand J, Rentz DM, Klunk WE, Mathis CA, Price JC, DeKosky ST,
Fischman AJ, Greenberg SM (2007) Imaging of amyloid burden and
distribution in cerebral amyloid angiopathy. Ann Neurol 62:229–234
31. Johnson KA, Sperling RA, Gidicsin CM, Carmasin JS, Maye JE, Coleman RE,
Reiman EM, Sabbagh MN, Sadowsky CH, Fleisher AS, Murali DP, Carpenter
AP, Clark CM, Joshi AD, Lu M, Grundman M, Mintun MA, Pontecorvo MJ,
Skovronsky DM (2013) Florbetapir (F18-AV-45) PET to assess amyloid burden
in Alzheimer's disease dementia, mild cognitive impairment, and normal
aging. Alzheimers Dement 9:S72–S83
32. Kadir A, Marutle A, Gonzalez D, Scholl M, Almkvist O, Mousavi M, Mustafiz T,
Darreh-Shori T, Nennesmo I, Nordberg A (2011) Positron emission
tomography imaging and clinical progression in relation to molecular
pathology in the first Pittsburgh Compound B positron emission
tomography patient with Alzheimer's disease. Brain 134:301–317
33. Kantarci K, Yang C, Schneider JA, Senjem ML, Reyes DA, Lowe VJ, Barnes LL,
Aggarwal NT, Bennett DA, Smith GE, Petersen RC, Jack CR Jr, Boeve BF
(2012) Antemortem amyloid imaging and beta-amyloid pathology in a case
with dementia with Lewy bodies. Neurobiol Aging 33:878–885
34. Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, Ziolko SK, Bi W,
Hoge JA, Cohen AD, Ikonomovic MD, Saxton JA, Snitz BE, Pollen DA,
Moonis M, Lippa CF, Swearer JM, Johnson KA, Rentz DM, Fischman AJ,
Aizenstein HJ, DeKosky ST (2007) Amyloid deposition begins in the striatum
of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci
27:6174–6184
35. Landau SM, Breault C, Joshi AD, Pontecorvo M, Mathis CA, Jagust WJ,
Mintun MA (2013) Amyloid-beta imaging with Pittsburgh compound B and
florbetapir: comparing radiotracers and quantification methods. J Nucl Med
54:70–77
Ikonomovic et al. Acta Neuropathologica Communications  (2016) 4:130 Page 23 of 24
36. Leinonen V, Alafuzoff I, Aalto S, Suotunen T, Savolainen S, Nagren K, Tapiola
T, Pirttila T, Rinne J, Jaaskelainen JE, Soininen H, Rinne JO (2008) Assessment
of beta-amyloid in a frontal cortical brain biopsy specimen and by positron
emission tomography with carbon 11-labeled Pittsburgh Compound B.
Arch Neurol 65:1304–1309
37. Leinonen V, Rinne JO, Virtanen KA, Eskola O, Rummukainen J, Huttunen J,
von Und Zu FM, Nerg O, Koivisto AM, Rinne J, Jaaskelainen JE, Buckley C,
Smith A, Jones PA, Sherwin P, Farrar G, McLain R, Kailajarvi M, Heurling K,
Grachev ID (2013) Positron emission tomography with [18 F] flutemetamol
and [11C]PiB for in vivo detection of cerebral cortical amyloid in normal
pressure hydrocephalus patients. Eur J Neurol 20:1043–1052
38. Leinonen V, Rinne JO, Wong DF, Wolk DA, Trojanowski JQ, Sherwin PF,
Smith A, Heurling K, Su M, Grachev ID (2014) Diagnostic effectiveness of
quantitative [18 F] flutemetamol PET imaging for detection of fibrillar
amyloid beta using cortical biopsy histopathology as the standard of truth
in subjects with idiopathic normal pressure hydrocephalus. Acta
Neuropathol Commun 2:46
39. Litchfield S, Nagy Z (2001) New temperature modification makes the
Bielschowsky silver stain reproducible. Acta Neuropathol 101:17–21
40. Litvan I, Hauw JJ, Bartko JJ, Lantos PL, Daniel SE, Horoupian DS, McKee A, Dickson
D, Bancher C, Tabaton M, Jellinger K, Anderson DW (1996) Validity and reliability
of the preliminary NINDS neuropathologic criteria for progressive supranuclear
palsy and related disorders. J Neuropathol Exp Neurol 55(1):97–105
41. Lockhart A, Ye L, Judd DB, Merritt AT, Lowe PN, Morgenstern JL, Hong G,
Gee AD, Brown J (2005) Evidence for the presence of three distinct binding
sites for the thioflavin T class of Alzheimer's disease PET imaging agents on
beta-amyloid peptide fibrils. J Biol Chem 280:7677–7684
42. McKeith IG, Ballard CG, Perry RH, Ince PG, O’Brien JT, Neill D, Lowery K, Jaros
E, Barber R, Thompson P, Swann A, Fairbairn AF, Perry EK (2000) Prospective
validation of consensus criteria for the diagnosis of dementia with lewy
bodies. Neurology 54(5):1050–1058
43. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS,
Hughes JP, van Belle G, Berg L (1991) The Consortium to Establish a Registry
for Alzheimer's Disease (CERAD). Part II. Standardization of the
neuropathologic assessment of Alzheimer's disease. Neurology 41:479–486
44. Moossy J, Zubenko GS, Martinez AJ, Rao GR (1988) Bilateral symmetry of
morphologic lesions in Alzheimer's disease. Arch Neurol 45:251–254
45. Murray ME, Lowe VJ, Graff-Radford NR, Liesinger AM, Cannon A, Przybelski
SA, Rawal B, Parisi JE, Petersen RC, Kantarci K, Ross OA, Duara R, Knopman
DS, Jack CR Jr, Dickson DW (2015) Clinicopathologic and 11C-Pittsburgh
compound B implications of Thal amyloid phase across the Alzheimer's
disease spectrum. Brain 138:1370–1381
46. National Electrical Manufacturers Association and The International
Electrotechnical Commision NEMA IEC Body Phantom Set. Last Updated:
2007. http://www.spect.com/pub/NEMA_IEC_Body_Phantom_Set.pdf
Accessed 9-18-2015.
47. Nelissen N, Van LK, Thurfjell L, Owenius R, Vandenbulcke M, Koole M,
Bormans G, Brooks DJ, Vandenberghe R (2009) Phase 1 study of the
Pittsburgh compound B derivative 18 F-flutemetamol in healthy volunteers
and patients with probable Alzheimer disease. J Nucl Med 50:1251–1259
48. Raji CA, Becker JT, Tsopelas ND, Price JC, Mathis CA, Saxton JA, Lopresti BJ,
Hoge JA, Ziolko SK, DeKosky ST, Klunk WE (2008) Characterizing regional
correlation, laterality and symmetry of amyloid deposition in mild cognitive
impairment and Alzheimer’s disease with Pittsburgh Compound B. J
Neurosci Methods 172:277–282
49. Re-Read Study to Compare the Brain Uptake of [18 F] Flutemetamol With
Brain Neuritic Plaque Density Determined Postmortem NCT02090855. Last
Updated: 7-11-2014. https://clinicaltrials.gov/ct2/show/NCT02090855?term=
NCT02090855&rank=1 Accessed 7-20-2015.
50. Rinne JO, Frantzen J, Leinonen V, Lonnrot K, Laakso A, Virtanen KA, Solin O,
Kotkansalo A, Koivisto A, Sajanti J, Karppinen A, Lehto H, Rummukainen J, Buckley
C, Smith A, Jones PA, Sherwin P, Farrar G, McLain R, Kailajarvi M, Grachev ID
(2013) Prospective flutemetamol positron emission tomography and
histopathology in normal pressure hydrocephalus. Neurodegener Dis 13:237–245
51. Rinne JO, Wong DF, Wolk DA, Leinonen V, Arnold SE, Buckley C, Smith A,
McLain R, Sherwin PF, Farrar G, Kailajarvi M, Grachev ID (2012) [(18)F]
Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar
amyloid beta detection in living subjects with normal pressure hydrocephalus:
pooled analysis of four studies. Acta Neuropathol 124:833–845
52. Rosenberg PB, Wong DF, Edell SL, Ross JS, Joshi AD, Brasic JR, Zhou Y,
Raymont V, Kumar A, Ravert HT, Dannals RF, Pontecorvo MJ, Skovronsky
DM, Lyketsos CG (2013) Cognition and amyloid load in Alzheimer disease
imaged with florbetapir F 18(AV-45) positron emission tomography. Am J
Geriatr Psychiatry 21:272–278
53. Sojkova J, Driscoll I, Iacono D, Zhou Y, Codispoti KE, Kraut MA, Ferrucci L,
Pletnikova O, Mathis CA, Klunk WE, O'Brien RJ, Wong DF, Troncoso JC,
Resnick SM (2011) In vivo fibrillar beta-amyloid detected using [11C]PiB
positron emission tomography and neuropathologic assessment in older
adults. Arch Neurol 68:232–240
54. Summary of Product Characteristics, Vizamyl. Last Updated: 10-16-2014.
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_
Information/human/002557/WC500172950.pdf Accessed 3-2-2015.
55. Thal DR, Beach TG, Zanette M, Heurling K, Chakrabarty A, Ismail A, Smith AP,
Buckley C (2015) [(18)F] flutemetamol amyloid positron emission tomography
in preclinical and symptomatic Alzheimer's disease: Specific detection of
advanced phases of amyloid-beta pathology. Alzheimers Dement 11:975–985
56. Thal DR, Ghebremedhin E, Orantes M, Wiestler OD (2003) Vascular
pathology in Alzheimer disease: correlation of cerebral amyloid angiopathy
and arteriosclerosis/lipohyalinosis with cognitive decline. J Neuropathol Exp
Neurol 62:1287–1301
57. Thal DR, Ghebremedhin E, Rub U, Yamaguchi H, Del TK, Braak H (2002) Two types
of sporadic cerebral amyloid angiopathy. J Neuropathol Exp Neurol 61:282–293
58. Thal DR, Rub U, Orantes M, Braak H (2002) Phases of A beta-deposition in
the human brain and its relevance for the development of AD. Neurology
58:1791–1800
59. Thurfjell L, Lilja J, Lundqvist R, Buckley C, Smith A, Vandenberghe R, Sherwin
P (2014) Automated quantification of 18 F-flutemetamol PET activity for
categorizing scans as negative or positive for brain amyloid: concordance
with visual image reads. J Nucl Med 55:1623–1628
60. Vemuri P, Whitwell JL, Kantarci K, Josephs KA, Parisi JE, Shiung MS, Knopman
DS, Boeve BF, Petersen RC, Dickson DW, Jack CR Jr (2008) Antemortem MRI
based STructural Abnormality iNDex (STAND)-scores correlate with
postmortem Braak neurofibrillary tangle stage. Neuroimage 42:559–567
61. Villemagne VL, Klunk WE, Mathis CA, Rowe CC, Brooks DJ, Hyman BT,
Ikonomovic MD, Ishii K, Jack CR, Jagust WJ, Johnson KA, Koeppe RA, Lowe
VJ, Masters CL, Montine TJ, Morris JC, Nordberg A, Petersen RC, Reiman EM,
Selkoe DJ, Sperling RA, Van LK, Weiner MW, Drzezga A (2012) Abeta
Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease. Eur
J Nucl Med Mol Imaging 39:209–219
62. Villemagne VL, McLean CA, Reardon K, Boyd A, Lewis V, Klug G, Jones G,
Baxendale D, Masters CL, Rowe CC, Collins SJ (2009) 11C-PiB PET studies in typical
sporadic Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 80:998–1001
63. Vizamyl™ (flutemetamol F 18 injection) Electronic Reader Training Program.
Last Updated: 2014. http://www.readvizamyl.com Accessed 8-4-2014.
64. Vonsattel JP, Myers RH, Hedley-Whyte ET, Ropper AH, Bird ED, Richardson
EP Jr (1991) Cerebral amyloid angiopathy without and with cerebral
hemorrhages: a comparative histological study. Ann Neurol 30:637–649
65. Wolk DA, Grachev ID, Buckley C, Kazi H, Grady MS, Trojanowski JQ,
Hamilton RH, Sherwin P, McLain R, Arnold SE (2011) Association
between in vivo fluorine 18-labeled flutemetamol amyloid positron
emission tomography imaging and in vivo cerebral cortical
histopathology. Arch Neurol 68:1398–1403
66. Wolk DA, Zhang Z, Boudhar S, Clark CM, Pontecorvo MJ, Arnold SE (2012)
Amyloid imaging in Alzheimer's disease: comparison of florbetapir and
Pittsburgh compound-B positron emission tomography. J Neurol Neurosurg
Psychiatry 83:923–926
67. Wong DF, Moghekar AR, Rigamonti D, Brasic JR, Rousset O, Willis W, Buckley
C, Smith A, Gok B, Sherwin P, Grachev ID (2013) An in vivo evaluation of
cerebral cortical amyloid with [18 F] flutemetamol using positron emission
tomography compared with parietal biopsy samples in living normal
pressure hydrocephalus patients. Mol Imaging Biol 15:230–237
68. Yamada M (2003) Senile Dementia of the Neurofibrillary Tangle Type
(tangle-Only Dementia): Neuropathological Criteria and Clinical Guidelines
for Diagnosis. Neuropathology 23(4):311–317
69. Yamaguchi H, Nakazato Y, Hirai S, Shoji M, Harigaya Y (1989) Electron
micrograph of diffuse plaques. Initial stage of senile plaque formation in the
Alzheimer brain. Am J Pathol 135:593–597
70. Ye L, Velasco A, Fraser G, Beach TG, Sue L, Osredkar T, Libri V, Spillantini MG,
Goedert M, Lockhart A (2008) In vitro high affinity alpha-synuclein binding
sites for the amyloid imaging agent PIB are not matched by binding to
Lewy bodies in postmortem human brain. J Neurochem 105:1428–1437
Ikonomovic et al. Acta Neuropathologica Communications  (2016) 4:130 Page 24 of 24
